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ABSTRACT 
LONG- ACTING INTRADUCTAL DRUG DELIVERY SYSTEMS FOR THE 
BREAST 
MIBIN KURUVILLA JOSEPH 
2019 
Breast cancer is the second most commonly diagnosed cancer in women in the US. Ductal 
carcinoma in situ (DCIS) is a premalignant lesion that has not metastasized through the 
regional lymph nodes to other organs. Currently, all breast cancers including localized 
breast cancers are treated with the same aggressive therapy. Localized drug delivery by 
direct intraductal injections into the mammary ducts can achieve high drug concentration 
at the target site. However, poor retention of drugs in the ducts limits the successful 
translation of this approach to the clinic. To this end, the main goal of this dissertation is 
to develop intraductal delivery systems that can sustain drug levels in the breast and reduce 
the frequency of intraductal injections.  
The first objective was to test the influence of particle size and formulations using 
polystyrene (PS) particles (100-1000nm) and poly lactic-co-glycolic acid (PLGA) 
formulations [microspheres (MS) and in-situ gel (ISG) and nanoparticles (NP)] and to test 
the retention in the breast and regional lymph nodes. In vivo imaging study in rats showed 
that PS 1000nm was retained in the breast for 3 days compared to PS 500 nm and PS100 
nm, which were retained for 2 days. The retention t ½ PS-1000nm particles was ~4-fold 
higher compared to 500nm, 100nm and free dye. PLGA MS and NP showed average 
particle size of 8.66 µm and 200 respectively.  In vivo fluorescence imaging study in rats 
showed that PLGA ISG and MS were retained in the ducts for 4 days compared to PLGA 
 
 
xv 
NP and free dye, which were retained for 2 days and 4 hours respectively. The breast 
retention t ½ of PLGA MS and ISG was > 4-fold higher compared to PLGA NP and free 
dye. Furthermore, PLGA MS and NP were transported and retained in the regional lymph 
nodes for 48 and 24 hours respectively. PLGA formulations followed a similar 
biodistribution trend when tested in pig.  PLGA ISG and MS were retained for 4 days and 
the free dye was retained only for few hours. 
The second objective was to develop intraductal formulations of tamoxifen (TMX) and 
study the in vivo biodistribution of TMX and its major active metabolites [4-
hydroxytamoxifen (4HT) and endoxifen (EDX)] following intraductal delivery.  The 
optimized PLGA MS and NP showed particle sizes of 9.12 µm and 274.1 nm respectively. 
In vitro release study showed that PLGA MS and ISG sustained release of TMX for > 3 
weeks, while PLGA NP sustained TMX release for 2 weeks. PLGA MS and ISG T retained 
TMX  in the breast for 2 weeks compared to PLGA NP and free TMX, which were retained 
6 and 3 days respectively.  The retention t ½ of TMX was delayed by >200 hours for PLGA 
MS and ISG compared to PLGA NP and free TMX. 4HT, a potent metabolite of TMX was 
generated in the mammary glands with PLGA MS and ISG and the levels were maintained 
above therapeutic levels for 2 weeks. No 4HT was detected in free TMX and PLGA NP 
groups after 2 and 7 days respectively. At the end of the treatment period (2 weeks), the 
amount of 4HT in the breast was 1.5 and 3.3-fold higher than free TMX group for PLGA 
MS and PLGA ISG respectively, and the concentration of 4HT was found to be above the 
therapeutic levels of 4HT in the breast. PLGA MS and ISG delayed the plasma t ½ by> 70 
hours compared to free TMX. PLGA MS and ISG sustained TMX, 4HT and EDX levels 
in the plasma (<5ng/ml) for 2 weeks and showed ~2 fold lower systemic exposure 
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compared to free TMX. The Cmax for free TMX was ~ 3- fold higher compared to PLGA 
MS and ISG.  PLGA MS and ISG showed significantly lower levels of TMX, 4HT and 
EDX in the organs. Intraductal TMX did not show any measurable levels of TMX, EDX 
and 4HT in the uterus.   
The final objective of the dissertation was to develop and test intraductal formulations of 
4HT in vivo.  To further prolong drug release upto a month, a combination of 4HT loaded 
PLGA microspheres and in situ gel (MSG) was used.  In vitro release study showed that 
PLGA MSG sustained 4HT release for ~1 month. MSG retained 4HT for ~1 month 
compared to free 4HT, which was retained only for 1 week. EDX a metabolite of 4HT was 
generated in the mammary glands treated with MSG. At day 28, EDX levels were 22-fold 
higher in MSG mammary glands compared to free 4HT. Pharmacokinetic studies in rats 
showed that MSG sustained 4HT and EDX levels in the plasma for 2 weeks. MSG delayed 
the plasma t ½ of 4HT and EDX by >3 fold compared to free 4HT. No 4HT was detected 
in the regional lymph nodes in the free 4HT group. On the other hand, MSG sustained 
therapeutic levels of 4HT in the regional lymph nodes for 14 days and was undetectable at 
day 28. 
Taken together, the findings from this dissertation demonstrate the feasibility of developing 
long acting intraductal formulations to prolong drug retention in the breast and reduce 
systemic drug distribution.  
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INTRODUCTION 
A. BREAST ANATOMY AND PHYSIOLOGY  
The human breast is a modified cutaneous exocrine gland and the skin over the breast 
connects to the underlying breast tissue through a facial layer and fibrous extensions of 
Coopers ligaments.1, 2  The human breast lies on the anterior thoracic wall with its base 
extending from the second to the sixth rib.3 Anatomically, the breast lies between the 
between the skin and underlying organs. The skin and nipple are attached to the breast 
through suspensory ligaments of cooper which are fibrous strands extending from the 
dermis into the breast. However, the peripheral boundaries of the mature human breast are 
not clearly defined with the exception at the deep surface where the gland overlies 
pectoralis fascia. Laterally, the breast extends over portions of serratus anterior muscle, 
over external oblique muscle inferiorly and over rectus sheath superiorly and medially into 
the sternum. The breast tissue comprises of epithelial and parenchymal cells and the 
stroma. The epithelial cells constitute 10-15% of the overall breast volume and the 
remainder of the volume is filled with components of the stroma. The breast is divided into 
upper inner, upper outer, lower inner and lower outer quadrant using two perpendicular 
planes intersecting at the nipple or nipple centroid line.4  
 
The human breast is composed of glandular (secretory) and adipose (fatty) tissues 
supported by Cooper’s ligaments (connective tissues) (Figure1).   The secretory tissue is 
drained by a network of ducts that stores and transports milk during lactation5.  The human 
breast consists of 15-20 lobes and each lobe is further divided into 20 to 40 lobules 
containing 10-100 alveoli (0.12mm in diameter)6. These lobules are composed of tubule 
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alveolar glands and it drains into a major lactiferous duct. The lactiferous ducts drain into 
lactiferous sinus (2-4mm)7 which ultimately opens through orifices onto the nipple.3  
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Figure 1: Anatomy of the breast  
Reproduced from https://visualsonline.cancer.gov/details.cfm?imageid=2170
4 
 
Breast Ductal System 
The human breast comprises of 15-20 mammary ductal networks but all of these ducts do 
not terminate as ductal orifices at the nipple (Figure2). 8 The ductal networks can be 
grouped into true mammary ducts and sebaceous glands. Studies 9, 10 have confirmed that 
only 5-9 ducts terminate at the nipple and are accessible from the outside. Even though the 
ductal systems are in close juxtaposition to each other, they are not connected. 8 There is 
increasing evidence that breast cancer originates from a single ductal system. The sick lobe 
theory describes DCIS as a lobar disease and the in situ tumor foci are localized in the 
single lobe of the breast. 11 Therefore, the variabilities within each of these ducts needs to 
be considered in designing appropriate treatment strategies. 8 For example, in patients with 
a genetic predisposition to breast cancer (BRCA1, BRCA 2), the specific ducts express 
surrogate markers before any histological changes appear. By utilizing these surrogate 
markers, high risk ducts can be accessed and treated effectively.  
 
 
5 
 
 
Figure 2: Breast duct anatomy 
Reproduced from https://visuals.nci.nih.gov/details.cfm?imageid=1810 
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Vascular and Lymphatic components in breast 
Three major arteries supply blood to the breast. About 60% of the blood supply is through 
the internal mammary artery arising from the internal thoracic artery. Around 30% of the 
blood supply is provided by the axillary and thoracoacromial arteries,  and the remainder  
through the posterior intercostal arteries12.   
 
The lymphatic system plays a prominent role in maintaining tissue fluid homeostasis. The 
extravasated blood plasma and proteins are collected in the interstitial space and this forms 
the lymph fluid. The lymphatic system is primarily divided into lymphatic capillaries, 
collecting vessels, lymph nodes, and lymphatic trunks and ducts. Studies by Sappey13 in 
the early 1870’s demonstrated that breast lymphatics are separate from the underlying torso 
with the lymphatics in the subareolar plexus and a small number of large lymphatic vessels 
draining into the axillary lymph nodes (Figure 3). In the superficial layer of the skin, the 
lymphatics capillaries are 20-70 µm in diameter and they drain into pre-collectors that are 
up to 70 - 150 µm in diameter. These capillaries drain to lymph collectors in the 
subcutaneous space and are 150 - 350 µm in diameter.  The lumen of lymphatic vessels are 
wider and more irregular than vascular capillaries and these are composed of single layer 
of endothelial cells and a discontinuous basement membrane of 10-50µm in diameter. 14 
Axillary lymph nodes accounts for more than 75% of lymphatic drainage of the breast.1, 15, 
16 The number of nodes in the axillary region are determined to be 20 to 30. The lymph 
nodes are classified in accordance with their relationship to the pectoralis minor muscle. 3, 
17 Level I lymph nodes (axillary vein, external mammary and scapular groups) are located 
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lateral to the pectoralis minor muscle. Lymph nodes found in the superficial and deep 
regions of pectoralis muscle are termed as level II lymph nodes (central and interpectoral 
group). Level III lymph nodes are located medial to the pectoralis minor muscle 
(subclavicular group).  
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Figure 3: Breast and adjacent lymph nodes 
Reproduced from https://visualsonline.cancer.gov/details.cfm?imageid=4347 
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B. BREAST CANCER 
Breast cancer accounts for 30% of all new cancer diagnosis in women and it is the second 
most commonly diagnosed cancer amongst females in the US. 18 In 2019 alone, the 
American Cancer Society estimates 268,600 new cases of invasive breast cancer and 
62,930 new cases of non-invasive (in situ) breast cancer. The majority of breast cancer 
originates in the epithelial cells lining the milk ducts. These malignant cells are 
characterized by uncontrolled cell division of epithelial cells within the ducts (in situ 
carcinoma) and if overlooked, eventually breaches the basement membrane and becomes 
invasive. 19, 20  
 
The exact cause of breast cancer is still unknown, but there are several risk factors which 
contribute to its development. There is a correlation between increased risk of developing 
breast cancer with an increase in age. The incidence rate of breast cancer doubles with 
every 10 years of age until menopause. 21 Other factors include limited blood supply to the 
ducts, 22 age at menarche and menopause, age at first pregnancy, and family history. 21 
Women with mutations in two genes, BRCA1 and BRCA2 are associated with increased 
risk of developing breast cancer. It is found that about 5-10% of breast cancer cases are 
due to this mutation and there is an 80% chance that these women will develop breast 
cancer during their lifetime. 21, 23 Cells that lack BRCA1 and BRCA 2 have deficiency in 
repairing the double strand breaks of DNA. The resulting genomic instability contributes 
to the underlying mechanism to breast cancer. 24 Breast cancer incidence rates are 
increasing in countries with historically higher incidence rates such as in Europe, as well 
as in regions with lower incidence rates which includes some countries in Latin America, 
10 
 
Asia and Africa. 25  Some of the factors that accounts for this rising trend are altered 
reproductive patterns such as age at first pregnancy, breast feeding duration, number of 
childbirths and lifestyle changes. 26, 27,28  
 
The majority of the breast cancers are localized and there is a lack of clear understanding 
of tumors that will eventually become invasive breast cancer. 29  Lymphatic system also 
plays a key role in cancer metastasis and breast cancer mortalities are primarily due to 
metastasis to other organs through the regional lymph nodes. The is pathological 
examination of lymph nodes is used for determining the stage of the cancer and metastasis. 
30 Generally, lymphatic drainage of the breast occurs to the adjacent lymph nodes and not 
to lymph nodes on the contralateral breast.  Hence, there is minimal chance of cancer 
metastasis to the contralateral nodes. 17 However, extensive blockage of lymphatic vessels 
results in subcutaneous lymphatic permeation to occur on the opposite breast.  
 
Types of Breast Cancer 
Breast cancer can be classified based on the stage of cancer31(Table 1), epithelial origin 
and molecular subtypes.  
Based on the epithelial origin32 breast cancers can be grouped into: 
I. DCIS (Ductal carcinoma in situ) is designated as Stage 0 in the AICC (American 
Joint Commission on Cancer) staging of breast cancer. DCIS is the abnormal 
proliferation of epithelial cells lining the mammary ducts (Figure 4). In situ refers 
to the fact that the malignant cells have not breached the basement membrane out 
into the stroma in the breast.  
11 
 
II. IDC (Invasive ductal carcinoma) remains the most prevalent type of invasive breast 
cancer and accounts for 70-80% of all cases (Figure 5). In IDC, the malignant cells 
spread throughout the breast tissue, blood vessels and the lymphatic system and 
metastasize to regional lymph nodes, and in advanced cases to the rest of the body. 
Around 75% of IDC are ER (estrogen receptor) and PR (progesterone receptor) 
positive and 15-20% expresses growth factor receptor HER2 (human epidermal 
growth factor receptor 2).  
III. ILC (infiltrating lobular carcinoma) is the second most common IDC. It is 
generally ER positive and found to occur more frequently in older women. ILC is 
characterized by a lack of cellular adhesion due to alterations in E-cadherin, a 
protein that aids in cell adhesion that is deleted or mutated.32 The lack of cellular 
adhesion gives rise to a single pattern of cells microscopically which is a 
distinguishing feature of ILC.  
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Table 1: Breast cancer classification based on stage of the cancer 
Stage Classification 
Stage 0 In situ 
Stage 1 Early stage – Invasive 
Stage II Early stage – Invasive 
Stage III Locally advanced 
Stage IV Metastatic 
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Figure 4: Ductal carcinoma in situ 
Reproduced from https://visualsonline.cancer.gov/details.cfm?imageid=4353 
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Figure 5: Invasive breast cancer 
Reproduced from https://commons.wikimedia.org/wiki/File:Invasive_breast_cancer.jpg 
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Molecular subtypes of breast cancer 
Breast cancer is also classified based on immunohistochemical expression of ER (estrogen 
receptor) PR (progesterone receptor), HER2 (human epidermal growth factor 2 receptor) 
and Ki67. 33, 34 The four main types are: 
1. Luminal A (ER+ or PR+, HER-2-) 
2. Luminal B (ER+ or PR+, HER-2+) 
3. HER2 (ER- or PR-, HER-2+) 
4. Triple Negative (ER- or PR-, HER-2-) 
 
1. Luminal A breast cancer 
Based on the molecular profile, majority of infiltrating lobular carcinomas belong to 
Luminal A subtype. This accounts for 50-60% of all cases of breast cancer35. The 
expression of estrogen receptors is similar between Luminal A breast cancers has low 
expression of cell cycle related genes (eg: MK167 and AURKA), and higher expression of 
luminal related proteins such as progesterone receptor and FOX 1. Luminal A tumor 
subtype also show a lower number of mutations across the genome. The patients with this 
type of cancer have better prognosis compared to Luminal B subtypes, but is associated 
higher incidence of bone metastasis in patients with tumor relapse. 35 The treatment options 
include aromatase inhibitors, selective estrogen receptor modulators and selective 
regulators like tamoxifen and fulvestrant respectively. 36, 37    
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2. Luminal B breast cancer 
This subtype represents 10-20% of all breast cancer cases. Luminal B subtype is more 
aggressive and has poor prognosis 33 compared to luminal A type. The main factor that 
distinguishes this subtype from luminal A type is the increased expression of proliferation 
genes such as MK167 and cyclin B1, and expression of HER2 and EGFR. The luminal B 
subtype has tumors with ER+/HER-2+ with high Ki67 expression. The treatment is 
challenging because of the poor prognosis. The luminal B type responds better to 
neoadjuvant chemotherapy achieving complete response in 17% of cases. 33, 37 Studies are 
underway to determine the mechanisms of metastasis vis-a-vis effective treatment 
approaches for this subtype. 37   
 
3. HER-2 positive breast cancer 
The human epidermal growth factor receptor 2 (HER-2) gene encodes a transmembrane 
tyrosine kinase receptor protein that is a member of epidermal growth factor receptor 
(EGFR).38 An increased expression of HER-2 gene/protein expression constitutes 10-34% 
of all invasive breast cancers.39 This tumor subtype is characterized by higher expression 
of HER-2 related and proliferation related genes and proteins. At the DNA level, this shows 
the highest number of mutations across the genome. This type of tumor constitutes 15-20 
% of all cases of breast cancer cases and has a poor prognosis.39 However in the last decade 
anti-HER2 therapy has significantly improved the survival of patients with HER2 positive 
breast cancer.40  
 
4. Triple negative/basal-like breast cancer 
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The basal like tumors represents 10-20% of all breast cancers. The term basal like is used 
because of the similarities in the expression of genes (CK5 and CK 17, EGFR. CD 44 etc.) 
in normal myoepithelial cells and luminal epithelium33 (CK8/18, Kit etc.), but at 
significantly lower levels than luminal subtypes. These tumors show a high response rate 
to chemotherapy; however, have a higher rate of relapse within the first three years and a 
worse prognosis than luminal types. One of the key features of this subtype is the absence 
of ER, PGR and HER-2. These tumor subtypes tend to be infiltrating carcinomas with 
aggressive metastasis visceral organs, mainly lungs, CNS and lymph nodes. 36 The standard 
systemic treatment for triple negative cancer follows the same principle as other types of 
breast cancer. 41 One of the most promising therapies to treat these tumors is poly-
ADPribose-polymerase-1 (PARP-1) inhibitors, which is associated with a higher response 
rate and clinical benefit. 42 The advance of multiomics have led to the discovery of targeted 
therapies which can be particularly beneficial for this subtype.  
 
C.THERAPEUTIC APPROACHES FOR BREAST CANCER 
Breast cancer treatment regimens depends upon several factors like the extent of tumor 
lymph node metastasis, grade of the tumor, hormone receptor status and HER2 
overexpression, age and menopausal status of the patient. The most common treatment 
modalities currently used are described below.  
1. Surgery 
2. Radiotherapy 
3. Chemotherapy 
4. Hormone Therapy 
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5. Targeted Therapy 
 
1. Surgery  
Currently most of the early stage tumors are removed by surgical approaches. 43 However, 
the major drawback is that the chance of tumor relapse is unpredictable. Adjuvant 
chemotherapy is recommended along with surgery, which results in unwanted side effects. 
44 In case of patients with larger tumor size and high nodal involvement at diagnosis, 
neoadjuvant therapy is recommended with the goal being to shrink the tumor to aid surgery. 
Earlier, the standard treatment for breast cancer was limited to mastectomy, which is the 
complete removal of breast tissue along with the underlying muscle tissue and the 
associated lymph nodes. 45 This procedure significantly impairs the quality of life of 
patients and several studies 46 show increased risk of depression and body image issues in 
these patients. However, improvements in mammographic screening techniques lead to 
early diagnosis and a reduction in mastectomy.  47  As a result, local resection of the tumor 
followed by radiotherapy with chemotherapy is favored for patients diagnosed with breast 
cancer. 48  
 
Breast conservation surgery (Lumpectomy) is an established procedure for women 
diagnosed with early stage breast cancer. It involves the surgical resection of tumor, 
axillary node dissection followed by radiotherapy of the affected breast.49 Almost two 
thirds of patients are eligible for breast conservation surgery, with an average presentation 
of tumor size at less than 2 cm. However lumpectomy does not completely eliminate the 
chances of tumor relapse in the conserved breast. The major factors that determine the local 
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recurrence within the conserved breast are the margin status and an extensive in situ 
component. Other factors include age (< 35 years) and nodal status, large tumor size (>2 
cm), and higher histological grade at the time of surgery.   
 
The choice of adjuvant chemotherapy depends on several factors ranging from the extent 
of spread of tumor locally or to the axillary lymph nodes. Depending upon the stage of 
cancer, sentinel lymph node technique allows for the removal of axillary lymph nodes 
bypassing the need for axillary curettage if these nodes are not invaded.50 Axillary lymph 
node dissection is associated with edema, numbness, pain and decreased mobility of the 
affected arm.  As a general procedure in breast conservation therapy, radiation therapy 
accompanies the treatment and the affected breast is irradiated with additional dose of 
radiation to the tumor excision region and to the lymph node regions.  
 
2. Radiotherapy 
Different types of radiation therapies such as external beam radiation therapy, 
brachytherapy and systemic radioisotope therapy and fractionation regimens are employed 
in many types of cancer including breast cancer. 51 Radiotherapy is also used to reduce the 
size of the tumor before lumpectomy and is also as a way to reduce the treatment burden 
to the patient undergoing chemotherapy. 52  With technological advancements, image-
guided treatment devices enabled more precise delivery of high intensity beams of 
radiation to tumor site with decreased damage to healthy surrounding tissue. However, the 
overall benefit from radiotherapy is unpredictable as some of the tumor cells resist radiation 
damage giving rise to recurrent tumors for which there are limited treatment options 
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available.53  Also, radiation therapy is expensive and time consuming and hence shorter 
treatment options are preferred by patients.54 
 
3. Chemotherapy 
The potential for the development of chemotherapeutic drugs dates back to the First World 
War when soldiers who underwent treatment after exposure to sulfur mustard gas 
developed lymphoid aplasia. Later, nitrogen mustards became the first chemical agents to 
be tested in clinic and showed remarkable results in lymphoma patients.55  Most of 
chemotherapy drugs reduce the rate of cell growth either by interacting with the DNA or 
by interfering with cell division. 56  
These drugs lack the ability to distinguish between normal and cancer cells and this non-
specificity result in serious side effects. They are used either as single agents or in 
combination to reduce the chances of cancer resistance towards a single agent. The drugs 
and drug combinations approved by USFDA to treat breast cancer are listed in Tables 2 
and 3. If the cancer is diagnosed at later stages, the goal of chemotherapy is palliative and 
treat the symptoms to improve quality of life.55 The common prognostic indicators for 
breast cancer include the size of tumor, grade, lymph node evasion and age. The presence 
of hormone receptors (estrogens and progesterone), overexpression of epithelial growth 
factor receptor 2 (HER2) and Ki67 index which quantifies the cellular proliferation levels 
have been included as prognostic indicators in the recent years.52  Administration of 
chemotherapy after surgery has improved the rates of disease free and overall survival rates 
is contingent upon the above mentioned prognostic markers. 57, 58 Anthracyclines and 
taxanes (paclitaxel and docetaxel) are considered to be most beneficial for adjuvant 
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chemotherapy. A randomized study showed improved survival upon administration of four 
cycles of doxorubicin/cyclophosphamide (AC) followed by four cycles of paclitaxel.59 In 
a larger randomized trial, patients were administered four cycles of AC followed by 
paclitaxel once in three weeks or weekly, docetaxel once in three weeks or weekly 
docetaxel. Improved survival rates were observed with four cycles of AC followed by a 
single dose of paclitaxel every week for 12 weeks.   
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Table 2: USFDA Approved chemotherapeutic agents for breast cancer  
Drug Route of Administration 
Paclitaxel Albumin- stabilized 
Nanoparticle Formulation 
IV 
Pamidronate Disodium IV 
Capecitabin Tablet 
Cyclophosphamide IV, tablet, capsule 
Docetaxel IV 
Doxorubicin Hydrochloride IV, liposomal 
Epirubicin Hydrochloride IV 
Eribulin Mesylate IV 
Everolimus Tablet 
Exemestane Tablet 
5-FU(Flurouracil) IV 
Gemcitabine Hydrochloride IV 
Methotrexate IV, Tablet 
Paclitaxel IV 
Thiotepa IV 
Vinblastine Sulfate IV 
IV – Intravenous, 5FU- 5 Fluorouracil 
Source: National Cancer institute (https://www.cancer.gov/about-cancer/treatment/drugs/breast) 
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Table 3: USFDA approved combination chemotherapy for breast cancer treatment  
Code Drugs used in combination 
AC Doxorubicin Hydrochloride, Cyclophosphamide 
AC-T Doxorubicin Hydrochloride, Cyclophosphamide, Paclitaxel 
CAF Cyclophosphamide, Doxorubicin Hydrochloride, Fluorouracil 
CMF Cyclophosphamide, Methotrexate, Fluorouracil 
FEC Fluorouracil, Epirubicin Hydrochloride, Cyclophosphamide 
TAC Docetaxel, Doxorubicin Hydrochloride, Cyclophosphamide 
Source: National Cancer institute (https://www.cancer.gov/about-cancer/treatment/drugs/breast) 
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Limitations of chemotherapy 
The process governing cell division (mitosis and apoptosis) are common to tumor cells and 
normal cells and chemotherapy affects both cell populations. The goal of treatment is to 
attain sufficient tumor cell killing while limiting toxicity towards normal cells. However, 
the therapeutic index for most conventional chemotherapy drugs is close to one and toxicity 
to the normal cells is dose limiting. 56 During the treatment period, the rapidly dividing 
cells of the GI tract, hair follicles, bone marrow and gonads are predominantly affected by 
these drugs. The common side effects include hair loss, nausea and vomiting, 
myelosuppression and reduced fertility. 56 Also, majority of these drugs can cause 
teratogenicity effects and hence harmful to the fetus. Long term effects of chemotherapy 
include the potential for development of cardiomyopathy caused by doxorubicin and 
pulmonary fibrosis due to treatment with bleomycin. 60 Some of the common side effects 
of chemotherapy associated with chemotherapy agents are listed in table 4.   
 
 
 
 
 
 
 
 
 
25 
 
Table 4: Common adverse effects of cytotoxic chemotherapy 55 
Tissue Manifestations Agents likely to cause toxicity 
Reticuloendothelial Neutropenia 
Anaemia 
Thrombocytopenia 
Alkylating agents, anthracyclines, 
taxanes, Topoisomerase inhibitors 
Gastrointestinal Diarrhoea 
Oral mucositis 
Nausea and vomiting 
Antifolates, fluoropyrimidines 
Various 
Neurological Peripheral sensory 
neuropathy 
Ototoxicity 
Vinca alkaloids, taxanes 
Cisplatin, oxaliplatin 
Renal Acute renal failure Cisplatin 
Hepatic Transaminitis Raltitrexed 
Cardiac Acute or chronic 
cardiomyopathy 
Cardiac ischaemic events 
Anthracyclines 
Fluoropyrimidines 
Respiratory Pulmonary fibrosis Bleomycin 
Bladder Haemorrhagic cystitis Cyclophosphamide 
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Others Hand-foot syndrome 
Vesicant 
Anaphylaxis 
Alopecia, fatigue, lethargy 
Subfertility/infertility 
Increased risk of second 
malignancy 
5FU infusion, capecitabine 
Doxorubicin, vincristine 
Taxanes 
Combination chemotherapy containing 
alkylating agents 
Reproduced from Corrie, P.G., 2008. Cytotoxic chemotherapy: clinical 
aspects. Medicine, 36(1), pp.24-28. 
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4. Endocrine/Hormone Therapy 
Hormone receptor positive (estrogen and progesterone) breast cancer constitutes 65-75% 
of all breast cancers. 61 In this subtype, the tumor cells are largely dependent on female 
hormones for their growth and survival. The serum concentrations of the major hormones 
estrogen and progesterone are regulated through hypothalamic-pituitary-gonadal axis. In 
pre-menopausal women, estradiol is synthesized by ovaries whereas in post-menopausal 
women, estradiol is produced from adrenal androgens in the peripheral tissues mainly 
adipose tissues. 62  
 
The two main classes of drugs used for endocrine therapy are i) selective estrogen receptor 
modulators (SERM’s) and ii) aromatase inhibitors (AI’s).  SERM’s binds competitively to 
the estrogen receptors and interfere with the DNA synthesis and eventually inhibit G0 to 
G1 cell cycle progression. 63 AI’s inhibit the enzyme aromatase which converts circulating 
testosterone and androstenedione to estradiol and estrone respectively by aromatization. 64 
Hence AI’s is proven to be beneficial in post-menopausal women, where the primary 
source of estrogen is depleted. The most commonly reported side effects of hormone 
therapy are hot flashes, weakness and tendency towards weight gain and depression. 52. 
Although rare, but serious, these agents also cause thrombo-embolic events and 
endometrial cancer. 52 There are also reports of reduced bone density resulting in increased 
fracture rate and an increase in the coronary artery events with these agents. 65 The USFDA 
approved endocrine therapy agents to treat breast cancer listed in Table 5. 
 
1. SERM’s 
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Estrogen is a steroid hormone that plays a major role in growth and function of breast, 
uterus and ovaries. It also plays a key role in maintaining bone density and lowering the 
cholesterol levels in the body. In case of ER+ cancers, it stimulates the growth of cancer 
cells in the breast and uterus. Estrogen mediates its action through estrogen binding 
receptors (ERα and Erβ)  that function as transcription factors which regulates the 
expression of estrogen responsive genes61, 66.  
 
SERM’s act as agonist to maintain the cholesterol levels and bone density, and has 
antagonistic effects in the breast tissue67. Tamoxifen is a widely used anticancer drug in 
post-menopausal women with axillary lymph node positive and in pre and post-menopausal 
women with lymph node negative ER+ cancers. It has also been used as a chemopreventive 
agent to reduce the risk of breast cancer in high risk and in pre and post-menopausal women 
with breast cancer68.    
 
2. Aromatase inhibitors 
Aromatase inhibitors are another class of drugs that are of significance in adjuvant therapy 
for breast cancer. In post-menopausal women in which the ovaries are dysfunctional, 
estrogen is produced peripherally by the conversion of androgens by the enzyme 
aromatase69, 70. Aromatase belongs to the family of CYP450 enzymes and it catalyzes the 
final step of estrogen biosynthesis. Three of the approved AI’s (Table 5) for treating breast 
cancers show better activity than tamoxifen, however the long-term safety of these agents 
is still under investigation. AI’s are considered to be standard treatment for postmenopausal 
women. The American Society of Clinical Oncology states that the adjuvant chemotherapy 
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should include an aromatase inhibitor as an initial therapy or after tamoxifen therapy for 2-
5 years71.   
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Table 5: USFDA approved hormone therapy drugs for breast cancer 
Drug Target 
Tamoxifen SERM 
Tamoxifen Citrate SERM 
Raloxifene SERM 
Toremefine SERM 
Fulvestrant EA 
Anastrozole AI 
Exemestane AI 
Letrozole AI 
AI – Aromatase inhibitor, SERM-Selective estrogen receptor modulator, EA estrogen 
antagonist 
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5. Targeted therapy 
A greater understanding of the biological factors that play a role in breast cancer has 
identified new molecular targets. Breast cancer cells sustain and proliferate by several 
growth factor receptors driven signaling pathways. Of note are the epidermal growth factor 
receptor (EGFR) family of tyrosine kinase receptors which includes four different types: 
EGFR (ErbB-1), ErbB-2 (HER2), ErbB-3 and ErbB-4.72  Each of these receptors possess 
a ligand binding domain in the extracellular space, a transmembrane domain and a tyrosine 
kinase containing domain in the cytoplasm inside the cell. Upon the binding of peptide 
growth factors to these receptors dimerizes,  which in turn activates kinase enzyme which 
then phosphorylates tyrosine residues73. Some of the known targets for tyrosine kinase 
inhibitors (TKI’s) include HER1, HER2, HER3, Insulin growth factor receptor (IGFR), 
hepatocyte growth factor receptor (C-MET), fibroblast growth factor receptor (FGF) and 
intracellular targets which includes Phosphoinositide 3-kinase (PI3K), protein kinase B 
(PKB/AKT), mammalian target of rapamycin (mTOR), extracellular signal-regulated 
kinase (ERK).74  
 
Human epidermal receptor (HER) family of receptors is classified into HER1, HER2, 
HER3 and HER4. Amongst these HER2 amplification is present in 10-34% of breast 
cancers 39 and is linked to poor prognosis. 75 In one of the trials, trastuzumab, a monoclonal 
antibody directed against HER 2-receptor showed early survival benefit in patients with 
HER 2 positive early stage breast cancer. In this study, trastuzumab was administered 
concurrently with anthracyclines (AC) based chemotherapy (AC followed by 
paclitaxel/trastuzumab) followed by 52 weeks of trastuzumab. Lapatinib is another small 
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molecule tyrosine kinase inhibitor directed against epidermal growth factor and HER2. A 
combination of Lapatinib and capecitabine improved the survival rates in patients with 
metastatic breast cancer. 76 Pertuzumab is another monoclonal antibody that binds to a 
different domain of HER 2 protein. A combination of trastuzumab and pertuzumab showed 
synergistic action in preclinical studies. 77 Overexpression of insulin-like growth factor 1 
receptor (IGF-IR) is associated with poor prognosis as well as resistant towards several 
drugs. 78 Activation of signaling pathways triggered by binding of ligands to these growth 
factor receptors are well characterized in breast cancer cell lines. Of significance are 
mitogen-activated protein kinase (MAPK) and PI3K/Akt/mTOR pathways and clinical 
trials are underway to test several inhibitor molecules targeting various aspects of these 
pathways. 78  (Table 6) 
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Table 6: Biological targeted therapy in development for the treatment of breast cancer79 
Agent Target Current Phase of 
Clinical Development 
Pertuzumab HER2 III 
TDM1 HER2 III 
Erlotinib EGFR II 
Afatinib EGFR, HER2 III 
Neratinib EGFR, HER2 III 
Aflibercept VEGF II 
Sunitinib PDGFR, VEGFR-1, VEGFR-2,c-KIT, 
FLT3 
III 
Sorafenib PDGFR, VEGFR-2, RAF II 
Axitinib PDGFR, all VEGFR, c-KIT II 
Vandetanib VEGFR, EGFR II 
Pazopanib PDGFR, all VEGFR, c-KIT           III 
Temsirolimus mTOR II 
Everolimus mTOR III 
Ridaforolimus mTOR II 
Cixutumumab IGF-1R II 
AMG 479 IGF-1R II 
Dasatinib Src II 
Bortezomib Proteasome II 
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Tanespimycin Hsp90 II 
Rataspimycin Hsp90 II 
Vorinostat HDAC II 
Iniparib PARP1 III 
Olaparib PARP1 II 
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D. LOCALIZED CHEMOTHERAPY  
The chemotherapy drugs approved for breast cancer are associated with short-term and 
long-term side effects. With the goal to minimize these side effects, localized delivery 
approaches have been explored. These approaches include transdermal, transpapillary 
(topical application on the nipple) and intraductal drug delivery.  
 
1. Transdermal delivery  
As the largest organ in the human body, skin provides convenient site for drug 
administration. However, the skin has naturally evolved to protect the entry of foreign 
molecules and to minimize the water loss from the body. The human skin is made up of 
epidermis, dermis and subcutaneous tissue (Figure 6). The skin’s barrier function is entirely 
accomplished by the outermost layer of the epidermis of the skin – stratum corneum (10-
15 µm thick). This layer is composed of compressed keratin filled corneocytes (terminally 
differentiated keratinocytes) embedded in a lipid rich matrix.80-83  The lipids in SC are 
different from phospholipids in cell membranes in the following aspects. 83 
a) Continuous phase and diffusion path from the surface to the base of the stratum 
corneum 
b) Unique in its composition which consists of ceramides, free fatty acids and 
cholesterol and absence of phospholipids 
c) Exists as multilamellar sheets  
d) Presence of saturated long chain hydrocarbons which facilitates highly ordered 
configuration 
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Figure 6: Skin structure.  
Image reproduced from https://visualsonline.cancer.gov/details.cfm?imageid=4604 
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Due to the presence of this formidable barrier, an ideal molecule for transdermal delivery 
should possess the following properties to cross the skin.  These include  molecular weight 
< 500 Da, Log P 1-3, aqueous solubility >1 mg/ml, dose < 1 mg per day and a low melting 
point81. Candidates that are currently approved have molecular weight of only up to a few 
hundred Daltons, partition coefficient predominantly favors lipids and the dose 
requirements of 1 mg or less per day.84  There are three major routes of drug absorption 
pathways after transdermal delivery.85, 86  
i) Transcellular route: The drug traverses through alternating layers of cells and 
extracellular matrix. This involves a series of partitioning between alternating 
hydrophobic and hydrophilic domains. Lipophilic molecules tend to follow this 
route of drug permeations.  
ii) Paracellular route: In this the drug molecules takes a tortuous path within the 
extracellular matrix without traversing through the cells. Hydrophilic molecules 
tend to favor this route of permeation.  
iii) Transappendgeal route: The drug molecules permeate through the hair follicles 
or sweat ducts and are also known as shunt pathway or transfollicular pathway.  
  
The simplest approach to enhance permeation involves formulation approaches ranging 
from modifications of partition coefficient (Ksc/veh) 83 and using different vehicles as well 
as using supersaturated drug solutions87 to other formulations like microemulsion 88 and 
liposomal systems.89 The most extensively researched enhancement method involves 
chemical enhancers that can reversibly compromise the skin barrier to allow molecules to 
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pass through the membrane. These includes alcohols, fatty acids, sulfoxides, esters, 
terpenes, surfactants and phospholipids to mention a few.90  
Due to its unique features of skin in the breast, the human breast has been explored for 
transdermal delivery. 91-94 These features include embryological origin of the breast as a 
skin appendage, lymphatic circulation and presence of fatty envelope (subcutaneous and 
retromammary). 95 Topical application of 4-hydroxytamoxifen resulted in higher local drug 
levels and minimal systemic exposure.91 Topical gel formulations of 4-hydroxy tamoxifen 
and endoxifen to the mammary glands achieved higher drug levels in the mammary glands. 
But, this approach resulted in systemic exposure of the drug, as the levels were similar for 
topical gel and systemically treated groups.95 In a preclinical study, topical toremifene was 
able to achieve higher breast concentrations in baboon model with undetectable serum 
concentrations.96 In another study, transdermal delivery of SERM’s were investigated for 
its permeation across porcine skin. Results showed significant enhancement in the 
permeation of SERM’s via breast skin.97   However, further studies are required to validate 
the drug localization in the breast ducts and its retention in the ducts.   
 
2. Transpapillary delivery 
Transpapillary delivery involves drug delivery through the ductal openings at the nipple. 
98, 99  
Despite being a disease of the ducts, delivery of drugs through the mammary papillae has 
not received considerable attention until recently. For the very first time Heard et al 98 
demonstrated the transpapillary delivery of tamoxifen and two other test compounds in 
vitro. In another study99, the effect of lipophilicity of molecules via transpapillary route 
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was investigated. The study found that hydrophilic molecules are better candidates for drug 
delivery via this route. In a follow up study100, delivery of macromolecules ranging from 5 
to 67 KDa was demonstrated in vitro. The study showed a decrease in the permeability of 
macromolecules with increasing molecular weight and higher permeation achieved 
through the nipple compared to breast skin.  In an attempt to enhance the permeation of 
hydrophobic molecules through this route, influence of hydro alcoholic vehicles on the 
permeation of 4-hydroxtamoxifen was investigated. The study showed that an increase in 
the alcohol concentration resulted in increased permeation of 4-hydroxytamoxifen to the 
mammary papilla serving as a depot releasing the drug after treatment.101 In a more recent 
study, the transport pathway through this route was characterized using model dyes. The 
results showed that hydrophilic molecule was mainly transported through transepidermal 
pathway whereas lipophilic via transductal route.  In another study102 by the same group, 
nanoemulsions with higher water content enhanced the penetration of hydrophobic dye into 
the nipple. In a follow up study103, the same group used liposomes to skew the permeation 
through the ducts.  This route has been explored for the therapeutic potential of a natural 
chemopreventive agent α-santalol. Results showed that transdermal delivery of the 
compound through the breast and mammary papilla enhanced local drug concentrations 
with undetectable levels in the plasma. Also, transdermal delivery of α-santalol reduced 
the tumor incidence and tumor multiplicity in rats. 104 
 
Despite the advantages of this route, further studies are needed to validate the amount drugs 
reaching the mammary ducts where 95% of breast cancers originate and also the 
localization of the penetrated drug molecules within the ductal network. Retention of drug 
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molecules in the mammary ducts is poor and despite an increased permeation through the 
nipple, the retention of these compounds in the mammary gland needs to be further 
investigated. Another limiting factor is the inability of this approach to distinguish the 
diseased duct vs healthy duct. Moreover, the limited surface area of the nipple restricts the 
delivery of only potent compounds for drug absorption via this route.  
 
3. Intraductal Delivery 
Intraductal delivery involves delivering therapeutic agents to the breast ducts by 
cannulating the diseased duct through the nipple. This allows for the delivery of 
therapeutic agents directly to the tumor forming ducts thereby enhancing drug levels at 
the tumor site. 
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This approach has precedence and the first study dates back to as early as 1842 by Ashley 
Cooper.105 In this study, Cooper intraductally injected colored waxes into the breast and 
described the human breast as separate lobes comprising of a central duct, its peripheral 
branches and associated glandular tissues. Subsequently this route has been explored for 
therapeutic and preventive options for breast cancer (Table 7). Earlier studies have also 
investigated the potential for mammary tumorigenesis in rat models after intraductal 
delivery of activated Raf.106 Results showed efficient expression of the protein and tumor 
induction in a small fraction of mammary epithelial cells in situ. Another study explored 
the delivery of adenoviral vectors carrying thymidine kinase gene107, followed by ip 
administration of ganciclovir. Results showed efficient transduction and ablation of 
proliferating cells (>90%) but the tumor incidence in treatment group was found to be 
higher compared to control.  The first chemopreventive study was performed by Yasuo 
Kamiyama108 and colleagues using a microtubule inhibitor, paclitaxel. Paclitaxel 
significantly reduced tumor burden at the end of 36 weeks in N-Methyl-N-nitrosourea 
(MNU) induced mouse model compared to ip injection. Moreover, intraductal paclitaxel 
did not produce any toxic side effects such as weight loss or local duct damage. Also, the 
cytotoxic effects were confined only to the developed tumor.108  
 
In a study by Sukumar et al109, 4-Hydroxytamoxifen and PEGylated liposomal doxorubicin 
(PLD) were investigated for chemoprevention and therapy in MNU-induced murine 
models. Intraductal 4HT showed chemopreventive effects comparable to subcutaneously 
administered tamoxifen group. However, no metabolites were reported to be produced in 
the mammary glands. Intraductal PLD once a week for 2 weeks resulted in complete 
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regression of tumors and the animals remained tumor free for 3 months. Pharmacokinetic 
studies showed that intraductal doxorubicin rapidly diffused out of the ducts into systemic 
circulation and peak plasma levels in was observed at 4 hours. However, PLD delayed the 
Tmax of doxorubicin to 24 hours due to delayed release of doxorubicin from liposomal 
formulations. In a clinical study conducted subsequently 110, the same group tested the 
feasibility and safety of PLD in females awaiting mastectomy. Intraductal delivery resulted 
in only a mild breast discomfort during drug delivery and mastectomy specimens showed 
a wide distribution of formulations in the duct reaching the terminal lobular units. This was 
one of the first clinical study which established the feasibility of intraductal delivery in 
human subjects. In the same study, other anticancer drugs (carboplatin, nanoparticle 
albumin-bound paclitaxel and methotrexate) along with 5-FU were tested for efficacy in 
MNU induced mammary tumors in rat. Amongst the agents tested, intraductal 5-FU 
showed significant protective effects against development of lesions as well as complete 
regression of established tumors. In this study, it is important to note that 5-FU showed 
efficacy in treated and untreated mammary glands bearing tumor indicating systemic 
exposure from the intraductally treated mammary glands.  
 
Sinko et al tested the influence of polymer molecular weight and architecture on intraductal 
retention. The breast t ½ of fluorescein disodium was increased up to 21.5 ± 2.7 hrs when 
conjugated with 40 KDa PEG compared to free dye which exhibited a t ½ of only 14.5 ± 
1.4 minutes. In a subsequent study22 by the same group, doxorubicin conjugated to higher 
molecular weight PEG carriers enhanced ductal retention (10-12 hours). Nanoemulsions 
In a more recent study, nanoemulsions containing ceramide was retained in the mammary 
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glands for 6 days.  111  The improved retention of ceramide in the mammary glands was 
attributed to the increased lipophilicity of ceramide (Log P > 6) suggesting improved 
retention of hydrophobic compounds in the mammary glands. Despite advancements in the 
field, the major challenge of poor intraductal retention remains to be further investigated. 
Additional studies are required to understand the formulation factors that influence the 
retention of drugs in the ducts for designing optimal formulations for intraductal delivery. 
This includes devising a formulation strategy to minimize the frequency of intraductal 
injections. To this end, the major goal of this study is to develop long-acting intraductal 
delivery systems which will sustain drug levels in the breast and reduce the frequency of 
injections. 
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Table 7: Summary of intraductal delivery studies 
 
Drug 
 
Year 
Preclinical/ 
Clinical  
 
Findings 
 
Paclitaxel 
 
2005 
 
Rats 
Intraductal paclitaxel significantly reduced the tumor burden. No toxic 
effects on normal cells108 
 
4-HT, PLD 
 
2006 
 
rats, mice 
4-HT and PLD caused regression of established tumors and prevented 
tumorogenesis. No long term changes in histopathology of mammary 
glands109 
5-FU, Carboplatin, 
paclitaxel nanoparticles, 
PLD, methotrexate 
 
2011 
 
rats, humans 
5-FU showed greatest antitumor effects amongst 5 agents in rats. Carboplatin 
showed beneficial effects in early and established tumors in rats. PLD well 
tolerated in humans with only mild discomfort110.  
 
PLD 
 
2012 
 
Mice 
Alteration in structure of mammary glands and tumor formation upon long 
term studies (80 weeks)112 
 
Curcumin 
 
2012 
 
Rats 
Able to lower the administered dose by 20 fold 
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Significantly lowered mammary tumor incidence with significant reduction 
in nuclear factor κβ113 
 
PEG 
 
2012 
 
Rats 
Intraductal retention increased with increase in molecular weight, retention 
decreased with increase in branching for same molecular weight, 
nanocarriers delayed the tmax 
 
PLD, Carboplatin 
 
2014 
 
Humans 
PLD showed mild erythema and swelling of breast at 50mg dose, carboplatin 
showed mild nausea and vomiting at 300mg dose, both drugs rapidly 
diffused out of ducts to systemic circulation114 
siRNA 2014 Mice Suppressed cell proliferation and reduced mammary tumor incidence by 
75%115 
 
225Ac-trastuzumab 
 
2016 
 
Mice 
Therapeutic efficacy of radioimmunoconjugate reduced the dose from 120 
nCi per mouse (IV) to 30-120 nCi per mouse (ID), No renal toxicity or loss 
of body weight upon intraductal administration116 
 
Cisplatin combined with 
PARP1 inhibitor 
 
2017 
 
Mice 
Ablation of mammary epithelial cells, delayed tumor onset from 153 to 239 
days, long term toxicity studies demonstrated tumor formation by 6.3% due 
to systemic exposure to cisplatin117 
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4-HT- 4-hydroxytamoxifen,  PLD – Pegylated liposomal doxorubicin, 5-FU – 5- Fluorouracil, PEG – Polyethylene glycol,  Ac 
– Actinium, PARP - Poly ADP ribose polymerase, ER is estrogen receptor
Ceramide 
nanoemulsions 
 
2018 
 
Rats 
Prolonged drug localization by more than 120 hours, no histological changes 
in the mammary glands111 
 
PEG-Doxorubicin 
 
2018 
 
Rats 
 
Intraductal retention is influenced by architecture of nanocarriers22 
Piplartine 
nanoemulsions 
2019  
Rats 
Charge of bio adhesive polymer does not have an impact on intraductal 
retention, mammary retention upto 120 days with no tissue damage118 
Fulvestrant 2019 Rats Intraductal fulvestrant showed comparable or better therapeutic efficacy in 
two preclinical animal models through degradation of ERα, inhibition of 
angiogenesis, ↓c-Myc and Cyclin D1, ↑ERβ 119 
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E. SCOPE AND GOAL OF THIS STUDY 
About 1 in 8 U.S. women will develop invasive breast cancer over the course of her 
lifetime. Ductal carcinoma in situ (DCIS) is pre-invasive breast cancer and accounts for 
20% cases of all diagnosed case of breast cancer. 120  DCIS is characterized by the 
proliferation of epithelial cells of milk ducts and terminal lobular units that have not 
breached the basement membrane and become invasive. 120  Although the precise pathways 
of tumor incidence and progression are poorly understood, majority of invasive carcinomas 
arise from DCIS. The standard treatment for DCIS is normally a combination of breast 
conservation surgery followed by radiotherapy with adjuvant chemotherapy depending on 
the stage of cancer. 31  
 
Systemic chemotherapy results in significant short-term and long-term side effects. 55, 121, 
122 Therefore, there is a need to develop localized delivery systems that can enhance drug 
concentration in the breast and minimize adverse effects. DCIS being confined to the 
breast, intraductal delivery enhanced drug concentration in the breast and minimized 
systemic exposure. 110, 123 Moreover, this approach showed improved efficacy in pre-
clinical and clinical studies. 114 108, 110, 119 However, the major drawback of this approach is 
the rapid diffusion of drugs into systemic circulation, warranting repeated intraductal 
injections to sustain drug levels in the ducts. 22, 124  To this end, the main goal of the present 
study is to develop long acting intraductal delivery systems to minimize the frequency of 
injections and to sustain drug levels in the breast.  
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Recent studies 22, 111 have used polymer drug conjugates and emulsions to sustain drug 
retention in the ducts. However, the critical determinants of developing long- acting 
delivery systems including the formulation matrix and particle size and its influence on 
intraductal retention is yet to be studied. Poly (lactic-co-glycolic acid) [PLGA] is a widely 
used polymer for developing sustained release formulations. 125-129 Several PLGA long-
acting formulations including microspheres and in situ gel systems are used for wide 
ranging applications. 125, 130, 131 However, these are yet to be explored for drug delivery via 
this route. In order to develop effective intraductal drug delivery systems, several critical 
parameters like particle size and formulation matrix needs to be investigated.  To this end, 
the major goal of this dissertation is to study the major formulation factors influencing drug 
retention vis-a-vis use the findings to develop optimal long-acting intraductal delivery 
system for breast cancer.  
 
The specific aims of the dissertation are: 
1) To investigate the effect of particle size and formulation on intraductal and lymph 
node    retention  
 
2) To develop and optimize poly (lactic-co-glycolic acid) formulations of tamoxifen 
and determine its pharmacokinetics in rats. 
 
3) To develop and test the pharmacokinetics of long-acting PLGA formulations of 4-
hydroxytamoxifen  
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CHAPTER I 
 
INFLUENCE OF PARTICLE SIZE AND FORMULATION ON BREAST AND 
LYMPH NODE RETENTION 
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1.1.       BACKGROUND 
Localized delivery to the breast through intraductal injections enhanced drug levels in the 
breast and reduced systemic exposure. Intraductal delivery (ID) has been effective in 
preclinical and clinical studies. 109, 110, 119, 123  Several anticancer drugs (carboplatin, 
methotrexate, 5FU, 4-hydroxytamoxifen, paclitaxel) delivered by this route have been 
shown to be effective in chemoprevention as well as chemotherapy in both chemical 
carcinogenesis as well as transgenic tumor models of breast cancer. 108-110 However, the 
major challenge of this approach is the rapid diffusion of drugs out of the ducts into 
systemic circulation. In a preclinical study, intraductal doxorubicin exhibited retention 
half-life of only 2 hours.22   In another study110, intraductal 5-FU showed superior efficacy 
in treated and untreated mammary gland which was attributed to the diffusion of 5-FU into 
systemic circulation. In a clinical study 132,  carboplatin rapidly distributed into the systemic 
circulation after intraductal injection, with a Tmax of ~30 minutes. The systemic and ID 
levels were similar in comparison, suggesting that small molecules diffuse rapidly out of 
the ducts. In another study, ID administration of PEGylated doxorubicin (liposome) 
showed superior efficacy than IV administration.110 The blood level of doxorubicin was 
fivefold lower than IV, with no systemic toxicity.  However, doxorubicin released from 
these liposomes caused local toxicity and edema.   
 
Taken together, there is a need to develop formulations that can prolong and sustain drug 
levels in the breast, minimizing systemic side-effects.  There have been some recent 
attempts to develop approaches to prolong drug retention in the breast.  Singh et al 
investigated the influence of molecular weight and polymer architecture (Linear 12, 20, 30, 
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40 KDa and Two-arm 60 KDa, Four-arm 20, 40 KDa and Eight-arm 20 KDa)  to prolong 
drug retention in the ducts. 124  The results showed that fluorescent labelled PEG showed 
ductal half-life in the range of 7-22 hours, while the half-life of free fluorescein was only 
15 minutes. The duct retention half-life increased with an increase in molecular weight (12 
– 60 KDa) and the particle sizes of the investigated polymers were in the range of 5-10 nm. 
Pharmacokinetic analysis showed a delayed the tmax to 32 ± 13.8 hours with two-arm 
60KDa carriers compared to free fluorescein which showed tmax of 0.5 hours. In a 
subsequent study22, doxorubicin labelled PEG nanocarriers of higher molecular weight and 
branching (40KDa, 4 arm) delayed the t1/2 to 13.1± 3.4 hours compared to free doxorubicin 
which exhibited t1/2 of 2.0± 0.4 hours. Histopathological studies showed that PEG 
conjugated doxorubicin induced only transient inflammation compared to free intraductal 
doxorubicin. Intraductal administration of nanoemulsions111 (<100 nm) were retained in 
the rat breast ducts for 120 hours. These nanoemulsions encapsulated a highly hydrophobic 
compound ceramide. In vivo whole-body images showed retention of formulations for 120 
hours. The improved retention of ceramide in the mammary glands was attributed to the 
increased lipophilicity of ceramide (Log P > 6) suggesting improved retention of 
hydrophobic compounds in the mammary glands. However, additional studies are required 
to investigate the retention of particles of larger size for designing formulations that can 
prolong and sustain drug levels in the breast.   
 
 The main goal of this study is to investigate the influence of polymeric particles ≥ 100nm 
and formulation on intraductal and lymph node retention using fluorescent probes. 
Fluorescent labeled polystyrene particles (100-1000nm) were used to study the influence 
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of particle size on breast duct retention. To translate the findings to clinical application, 
poly lactic-co-glycolic acid (PLGA), a US-FDA approved polymer was used for preparing 
nanoparticles (NP), microspheres (MS) and in-situ gel (ISG) formulations. PLGA has been 
extensively studied as a drug delivery system due to its biodegradability, tunable 
physicochemical properties and the ability to form different delivery systems.15 
Furthermore, there are several PLGA based long-acting parenteral formulations in clinical 
use.16 The breast retention and lymph node distribution after ID delivery of different 
formulations were studied using in-vitro and in-vivo imaging techniques in rats and pig.   
 
The specific aims of this study are: 
1. To investigate the influence of particle size on ductal retention and biodistribution 
using polystyrene carriers of different particle size 
 
2. To investigate the influence of PLGA formulations (microparticles, nanoparticles 
and in-situ gel) on ductal retention and biodistribution. 
 
 
 
 
 
1.2.    MATERIALS AND METHODS 
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Poly (lactic-co-glycolic acid) (LA:GA = 75:25, 65-75 KDa and 25 KDa, LA:GA = 50:50, 
5-10 KDa) was purchased from Akina, Inc. (West Lafayette, IN). Cyanine 5.5 carboxylic 
acid (Cy 5.5) was procured from Lumiprobe (Hallandale Beach, FL, USA). The isoflurane 
was obtained from VetOne, Boise, ID and Veet hair removing cream was obtained from 
Reckitt Benckiser North America (Parsippany, NJ). Polystyrene particles (NIRexTM) 
labeled with Near IR dye was obtained from Phosphorex (St. Hopkinton, MA). All other 
reagents were purchased from Sigma-Aldrich (St. Louis, MO).  
1.2.1. Animals 
Female Sprague Dawley Rats (3-4 weeks old) were obtained from USD animal facility and 
housed in South Dakota State Animal Resource Wing. The animals were maintained on a 
12-hour light/dark cycle in a temperature-controlled environment with food and water were 
given ad libitum. The animals were acclimatized for 1 week before starting the study. 
 For the pig study, 5-6-month-old gilt was procured from South Dakota State University 
Swine Education and Research Facility. The animal was maintained on a 12-hour light/dark 
cycle in a temperature-controlled environment and fed a standard finisher diet and was 
acclimatized for 1 week prior to initiating the study. All animal experiments were 
performed with approval from the Institutional Animal Care and Use Committee (IACUC) 
at South Dakota State University. 
 
 1.2.2.   METHODS 
1.2.2.1 Preparation of PLGA microparticles 
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Microparticles were prepared by oil-in-water (O/W) emulsion method reported in the 
literature. 133 Briefly, PLGA polymer (500mg) and Cy5.5 (1mg) were dissolved in 5 ml 
methylene chloride (DCM). The organic phase was added dropwise into an aqueous phase 
containing 1% PVA. The mixture was then emulsified by homogenized at 10,000 rpm for 
1 minute to form o/w emulsion. The resulting emulsion was then stirred at 300-400 rpm 
for 3 hours to allow the solvent to evaporate.  The microparticles were then separated by 
centrifugation at 4000 rpm for 20 minutes. The pellet was washed with distilled water, a 
total of three times and freeze-dried. The formulation was stored at 4°C for further studies. 
1.2.2.2. Preparation of PLGA nanoparticles 
PLGA nanoparticles were prepared by reported emulsion solvent evaporation method.134 
Briefly, 100 mg of PLGA was dissolved in 4ml methylene chloride containing Cy5.5 
(1mg). The organic phase was added dropwise into an aqueous phase containing 1% PVA. 
This was then sonicated using a probe sonicator set at 50W of energy output for 1 minute 
to form oil-in-water (o/w) emulsion. The resulting emulsion was then stirred at 300-400 
rpm for 2-3 hours to remove the organic solvent. The nanoparticles were separated by 
ultracentrifugation (20,000 rpm) for 20 minutes, washed with distilled water three times. 
The pellet was lyophilized and was stored at 4°C for further use.  
 1.2.2.3. Preparation of PLGA in-situ gel 
PLGA in situ gel was formed by phase inversion process, where the polymer in organic 
solvent undergoes sol to gel transition on contact with an aqueous medium.135 In situ gel 
was prepared by mixing PLGA of different copolymer ratios and molecular weights in N-
methyl-2-pyrrolidone (NMP) using a previously reported method with slight modification. 
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136, 137 PLGA with different copolymer ratios of LA: GA and molecular weights (50:50 and 
75:25 of molecular weights 5-10 KDa and 10-15 KDa respectively) were used to prepare 
15 wt% in-situ gel to achieve the desired syringeability and sustained release characteristics 
for intraductal injection. For forming 15 wt% gel, 75 mg of PLGA 75:25 (10-15 KDa) and 
75 mg PLGA 50:50 (5-10 KDa) was weighed into glass vials and dissolved in 1 ml of NMP 
by placing on a continuous shaker and kept overnight to completely dissolve the polymer. 
Cy5.5 was dissolved in NMP and added into polymer solution and used for in vitro release 
studies. For intraductal injection, the polymer was dissolved in NMP overnight and Cy5.5 
was dissolved in the polymer solution 30-60 minutes prior to the injection.  
1.2.2.4. Characterization of PLGA formulations 
The particle size and zeta potential of nanoparticles were measured by DLS on a Malvern 
Zetasizer Nano ZS (Malvern Instruments Inc., Southborough, MA). The morphology of 
PLGA formulations was characterized using Scanning Electron Microscopy (SEM). The 
particle size of microparticles was measured using SEM by measuring the size of 50 
particles with Smart Tiff V3 (Carl Zeiss, MA). The ex vivo fluorescence intensity of 
formulations was measured using spectrofluorimetry (SpectromaxM2, Molecular 
Devices, Sunnyvale, CA) using 690 and 750 nm as the excitation and emission 
wavelengths. Encapsulation and loading efficiency of microparticles and nanoparticles 
were calculated using the following equation: 
 
 
 
Weight of Cy 5.5 in the formulation Encapsulation Efficiency (%) = 
Weight of Cy 5.5 initially added 
X 100 
Weight of Cy 5.5 in the formulation Loading Percent (%) = 
          Total Weight of the formulation 
X 100 
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1.2.2.5. In vitro release study 
In vitro release of Cy 5.5. from the formulations were studied using a reported method with 
slight modifications.138-140 Briefly, 5-10 mg of microparticles and nanoparticles were 
dispersed in 1 ml of release medium (PBS, pH 7.4 containing 1% w/v Tween 80) in an 
Eppendorf tube and was placed in an orbital shaker water bath (shaken at 120 per minute) 
at  370C. At each time point, the tubes were centrifuged at 10,621 x g for 10 minutes and 
1 ml of the supernatant was removed for analysis. The pellet was redispersed in 1 ml of 
fresh release medium to maintain the sink conditions. The supernatant was analyzed using 
fluorescence spectroscopy to determine the dye concentration in the release medium. For 
in-situ gel, 10µg equivalent of the gel was injected into 1 ml release medium using 27 G 
needle to form the gel and the release study was carried out as described above.   
1.2.2.6. In vivo studies 
Intraductal injections were performed using a previously established method. 109 One day 
prior to starting the study, rats were anesthetized and hair around the nipple region was 
removed using a depilatory cream. Female SD rat was anesthetized using isoflurane and 
placed under a surgical microscope. Keratin plug from the mammary gland was removed 
by gently holding the nipple using a tweezer and wiping with 70% alcohol. The 
formulations were injected using 27-31 G needle into one pair of the inguinal mammary 
glands. For lymph node retention studies, thoracic mammary glands were used for 
introduction injection, since it drains into the axillary lymph node. This is consistent with 
the breast to axillary lymph node drainage in humans. The amount of Cy5.5 (1.5 mcg) 
injected was kept constant for all the formulations.  For microparticles and nanoparticles, 
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0.5 to1.5 mg particles were dispersed in 150 µl of PBS containing 0.05% w/v Tween 80 
and vortexed for 30-60 seconds before injection. For in-situ gel, 100 µl of the formulation 
was used for intraductal injection. Free Cy5.5 was dissolved in a minimal amount of NMP 
followed by dilution with PBS containing 0.05% w/v Tween 80. Similarly, fluorescent 
labeled polystyrene particles (1% w/v) were injected into the inguinal mammary gland and 
an equivalent amount of the free dye was used for comparison. The animals were 
anesthetized and imaged at different time points after injecting the particles using Bruker 
In Vivo Extreme II optical system. The animals were then allowed to recover back in their 
cages. 
 For the pig study, the animal was anesthetized by intramuscular injection of TKX (Telazol 
and Xylazine at 50mg/ml each and ketamine at 100mg/ml; 2.5m/50kg body weight). The 
hair around the nipple region was removed using hair removing cream one day before 
starting the study. Before starting the study, alcohol swab (70% ethanol) was used to 
remove the keratin plug. The PLGA formulations were dispersed in 500-1000µl of PBS 
containing 0.05% w/v Tween 80 and injected into the mammary glands using 27G blunt 
needle. Consistent with the 3R (replacement, reduction, and refinement) principles related 
to animal use in research, we used one pig to test all the formulations. All seven pairs of 
the mammary gland were utilized for the study (Figure S1). Since the mammary glands are 
not connected, the chance of spill-over from one mammary gland to another is very limited. 
We used 2-3 teats for each formulation and the breast distribution was studied at different 
time points (2 hrs and 4 days). At the end of the treatment, the animal was euthanized using 
an IV injection of pentobarbital (1ml/10 lb). The mammary glands were excised and 
imaged using in vivo imager. 
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1.2.2.7. Ex-vivo and In-vivo imaging 
The distribution of fluorescently labeled polystyrene particles (0 - 3 days), PLGA 
formulations (0 - 4 days) and the free dyes was measured by whole-body imaging using 
Bruker In Vivo Xtreme II optical imaging system. In a separate set of experiments, to study 
the lymph node retention, the rat was euthanized by CO2 asphyxiation at 2, 24 and 48 hours 
to excise the breast and axillary lymph nodes and imaged using in-vivo imager. For 
polystyrene particles, the ex vivo and in vivo fluorescence intensity was measured using 
the following instrument settings: Excitation/Emission 730/790nm, Bin 1x1 and f stop 1.1. 
For in vivo and ex vivo imaging studies of PLGA formulations, the fluorescence intensity 
was measured using the following instrument settings: excitation/emission: 690/750nm; 
Bin: 1x1 pixels; Exposure time: 20 seconds, f-stop of 1.2, FOV: 19. To compare the 
different treatment groups, the data was plotted as percentage of the initial fluorescence 
signal against time and the pharmacokinetic parameters (elimination rate constant and 
retention half-life) were determined by non-compartmental analysis using PK solutions 
software.124  The elimination rate constant (k) was determined from the regression analysis 
of semi-logarithmic plot of fluorescence intensity vs time. Retention half-life (t1/2) is 
defined as the time at which the fluorescence intensity becomes 50% of the initial value.  
 
1.2.2.8. Mammary whole mount 
At the end of the treatment, the rat was euthanized and mammary whole mounts were 
prepared using a literature reported method with slight modifications.124  Briefly, mammary 
glands were dissected and mounted onto a glass slide and fixed in 
chloroform/isopropanol/acetic acid (6:3:1) for 6 hours. The glands were then defatted using 
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acetone for 2-3 hours. The slides were then stored in methyl salicylate and the images were 
captured using a confocal microscope with 10X objective.  
 1.2.2.9. Fluorescence microscopy 
To visualize the distribution of PLGA formulations in the breast, the rat was euthanized, 
and the mammary gland was excised. The tissue was snap-frozen in optimum cutting 
temperature (OCT, Tissue Tek, Torrance, CA) medium placed in hexane under liquid 
nitrogen. The OCT block was sliced to 8-10 µm thick sections in a cryostat (UV800, Leica 
Microsystems, Bannockburn, IL) at -25ºC. The section was dried for 6 hours at 37 ºC and 
the coverslip was sealed using CytoSeal (Vector laboratories, Burlingame, CA). The tissue 
sections were then observed under an Olympus FluoView 1200 (Center Valley, PA) 
confocal laser scanning microscope (excitation/emission wavelength: 682/703 nm) at 20X 
magnification. 
 1.2.2.10. Histology 
To test the local tissue toxicity of the formulations, in a separate set of experiments, the 
rats were euthanized seven days after intraductal administration of PLGA formulations. 
The mammary glands were excised, and the tissue was fixed in 10% buffered neutral 
formalin for 24 hours at room temperature. The tissue was embedded in paraffin and 6 µm 
sections were prepared using a microtome (Olympus CUT 4060E, Center Valley, PA). The 
sections were stained with hematoxylin-eosin and examined under a light microscope 
(Olympus AX70, Center Valley, PA) for histological changes at 40X magnification. 
1.2.2.11. Statistical analysis  
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All the experiments were conducted in triplicates. The data is represented as a mean ± 
standard deviation. The groups were compared by Students t-test and One-way analysis of 
variance (ANOVA) using Minitab® statistical software (Minitab Inc., State College, PA) 
at a significance level of p<0.05. 
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1.3.  RESULTS AND DISCUSSION 
DCIS is confined to the breast and current systemic therapies are associated with significant 
physical and emotional distress, impacting the quality of life in women with preneoplasia, 
who are otherwise healthy.120, 141, 142 Alternatively, intraductal delivery of anti-cancer 
agents through cannulation of the diseased ducts is an effective and safe ‘chemical 
mastectomy’ approach for eradicating premalignant lesions with reduced systemic 
toxicity.108-110, 113, 123 Poor retention of drugs is a major challenge and it is important to 
understand the factors that influence drug retention in the breast to develop effective 
formulation strategies for intraductal drug delivery. The main objective of this preliminary 
study is to understand the influence of particle size and formulation on retention and 
distribution in the breast and regional lymph nodes. 
 1.3.1. Effect of particle size on breast retention and distribution 
To understand the influence of particle size, fluorescent-labeled polystyrene particles in 
three size ranges (100, 500 and 1000 nm) were tested. The commercially available 
polystyrene particles were used due to their uniform size (Table 8) and its reported use for 
in-vitro and in-vivo imaging studies.143 As shown in Figure 7, after intraductal injection in 
rats, the nanoparticles and microparticles showed higher retention compared to the free 
dye. The fluorescence from the nanoparticles (100 and 500 nm) and microparticles was 
observed till 2 and 3 days respectively. On the other hand, there was hardly any 
fluorescence observed for the free dye after 6 hours (Figure 7). The results were also 
supported by whole-mount imaging studies. The whole-mount images of the  
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breast showed intense fluorescence for the microspheres and there was hardly any 
fluorescence seen for the free dye (Figure 8
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Table 8: Characteristics of Polystyrene particles 
Particles Particle Size (nm) PDI Zeta Potential (mV) 
PS 100 nm 99.21 ± 2.37 0.10 ± 0.03 -53 .3 ± 0.90 
PS 500 nm 502.5 ± 4.85  0.18 ± 0.04 -51.26 ± 0.56 
PS 1000 nm 1006 ± 3.05 0.32± 0.13  -48.3 ± 0.50 
Data is Mean ± S.D (n=3); PS is polystyrene; PDI is polydispersity index
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Figure 7:  Representative images (n=3) showing distribution of polystyrene (PS) particles of different particle sizes (100nm, 
500nm and 1 µm) in the breast. Free Dye was used as a control. The images were captured using in-vivo imager from 0-72 hours. 
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Figure 8:  Representative mammary gland whole mount images of rat after treatment with polystyrene (PS) particles and free 
dye after 72 hours. The whole mount was imaged under 10X using a confocal microscope.  
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The elimination of the particles from the breast decreased with time (Figure 9). The 100 to 
500 nm PS particles showed similar retention half-life, but an increase in the particle size 
from 500 nm to 1000 nm increased the half-life by five-fold (Table 9). The fluorescence 
from the free dye declined rapidly. Based on qualitative analysis, the fluorescence in the 
various organs was high with the free dye followed by the 100 nm and 500nm. On the other 
hand, relatively lesser fluorescence was observed in the organs for 1000 nm particles 
(Figure 10).  
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Table 9: Kinetic parameters of Polystyrene particles 
Formulation k (h-1) t ½ (hrs) 
Polystyrene 1µm 0.007 ± 0.0005 ab 94.87 ± 4.12 abc 
Polystyrene 500nm 0.029 ± 0.002 a 24.15 ± 3.16 a  
Polystyrene 100nm 0.033 ± 0.11 a 22.35 ± 4.72 a  
Free Dye 0.662 ± 0.06 1.06 ± 0.16 
The data represents mean ± S.D (n = 3). ‘k’ is the elimination rate constant; t1/2 is the 
retention half-life, i.e. time at which the fluorescence intensity is 50% of the initial value. 
‘a’ is significant in comparison to Free Dye; ‘b’ is significant to Polystyrene 100 nm; ‘c’ 
is significant to Polystyrene 500nm. The values are significant at p < 0.05. 
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 Figure 9: Fluorescence intensity profiles of polystyrene particles (100nm, 500nm and 
1µm) expressed as percentage of initial fluorescence. Free dye was used as control. Each 
value represents mean ± S.D (n = 3). * is significant compared to free dye (p <0.05). 
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Figure 10: Representative ex-vivo fluorescence images of different organs after intraductal injection of polystyrene (PS) 
particles (1µm, 500nm and 100nm). The organs and mammary glands were excised and imaged at 72 hours. 1 – liver, 2- spleen, 
3- mammary gland, 4- kidneys, 5- lungs, 6- heart) 
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Earlier studies have shown that size and polymer architecture influence the formulation 
retention in the breast.22, 124   Gu et al showed that the retention half-life of doxorubicin 
increased linearly with increase in molecular weight of PEG from 5-40 kDa (hydrodynamic 
radius of 3-7 nm).22 The retention half-life ranged from 2 to 13 hours. Similarly, the 
retention half-life of fluorescein-conjugated PEG (12-40 KDa; 5-10nm) showed a retention 
half-life of 7-22 hours.124  On the other hand, the retention half-life of free dye and 
doxorubicin was 15 minutes and 2 hours respectively. 22, 124 Multi-arm (two, four and eight-
arm) PEG polymers showed similar or lower retention half-life than the linear PEG. 22, 124 
Carvalho et al studied the breast retention nanoemulsions (<100nm) in rats.111, 118 The 
nanoemulsions were retained in the breast for up to 5 days with an elimination half-life of 
20-30 hours, which is consistent with the half-life observed for 100 and 500 nm particles 
in our study. The half-life for the free dye (Alex Fluor) was around 2-3 hours. 118 On the 
other hand, the free ceramide was found to be retained in the breast for 48 hours.111 The 
authors did not find any significant difference in the retention between negative and 
positively charged nanoemulsions. However, as is evident from these studies, the 
physicochemical properties of the molecule including Log P and molecular weight 
influence ductal retention in the breast.  
 
Results from our study and the earlier studies suggest that an increase in molecular weight 
and particle size limits diffusion through the ducts. Furthermore, hydrophilic molecules are 
cleared rapidly from the breast compared to hydrophobic molecules.22, 111, 118, 124 The slower 
clearance of hydrophobic molecules can be attributed to the binding to the breast tissue.111 
On the other hand, an increase in molecular weight and particle size can limit the diffusion 
71 
 
through the ducts. Taken together, the results from this study for the first time demonstrate 
the retention of particles ≥ 100 nm in the breast. 
 1.3.2. Preparation and characterization of PLGA formulations. 
To develop clinically relevant formulations, we used PLGA, a US-FDA approved polymer. 
PLGA is biodegradable which under physiological conditions undergoes hydrolysis 
through the labile ester groups. The degradation time can be customized from weeks to 
years based on the route and delivery application by adjusting the lactic acid/glycolic acid 
ratio and molecular weight.144 Given the versatility of PLGA, it is widely used for sustained 
release applications by various routes of administration. 144 In this study, we used Cy 5.5 
loaded PLGA microspheres, nanoparticles and in-situ gel for studying the influence of 
formulation on breast duct retention. 
  
PLGA microspheres and nanoparticles showed a spherical morphology (Figure 11). PLGA 
microspheres and nanoparticles had an average particle size of 8.66 ± 3.25µm and 200 ± 
17.08 nm with a low PDI value. (Table 10)   
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Table 10: Properties of Cy 5.5 loaded PLGA formulations. 
Formulation Particle size  Zeta potential  
(mV) 
PDI Encapsulation 
Efficiency (%) 
Loading 
Percent (%) 
PLGA 
Microparticles 
8.66 ± 3.25µm* -31.75 ± 1.12* 0.121 ± 
0.045* 
63.47 ± 2.92* 0.15 ± 0.04* 
  
PLGA 
Nanoparticles  
200 ± 17.08 nm -21.12 ± 2.73  0.229 ± 
0.089  
36.02 ± 3.07 0.11 ± 0.08 
 (PDI) polydispersity index; Each value represents mean ± S.D (n = 3); (PDI) 
polydispersity index; * is significant compared to PLGA Nanoparticles  
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Figure 11: Scanning electron microscopy (SEM) images of PLGA formulations 
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In-situ PLGA gel was prepared by the phase inversion method using NMP as the organic 
solvent. When the PLGA suspension in NMP comes in contact with the aqueous fluid in 
the injection site precipitates to form a gel.135 NMP is the most commonly used solvent for 
in-situ PLGA gels, because of its solvating ability and its safety profile.136 The SEM image 
shows the porous structure of the PLGA gel (Figure 11), which is consistent with the 
literature.145   
  
One of the goals for developing intraductal formulations is to minimize the frequency of 
injections is by sustaining drug release for prolonged periods in the breast. As can be seen 
from the in vitro release studies (Figure 12), all the three formulations sustained the release 
of Cy 5.5. A biphasic release profile was observed for all the three formulations and the 
release profile is consistent with sustained release characteristics of PLGA formulations. 
146, 147 A higher burst release was seen with the nanoparticles compared to the other two 
formulations. The higher release can be attributed to the larger surface area of the 
nanoparticles compared to microparticles.148 On the other hand, there was no significant 
difference in the release profile between the microparticles and in-situ gel. Around 40% of 
the dye was released in 96 hours from the nanoparticles, while only 8% and 11% of the 
dye was released from in-situ gel and microparticles respectively (Figure 12). The slower 
release in addition to maintaining the drug levels in the breast can also reduce the local 
tissue toxicity of chemotherapeutic agents such as doxorubicin.12 
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Figure 12: In vitro release profile of Cy5.5 from PLGA microspheres, nanoparticles and 
in-situ gel. The data represents mean ± S.D (n = 3). * is significant in comparison to ISG 
(p <0.05) 
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1.3.3. Effect of PLGA formulations on retention and distribution in the breast  
The next goal was to test the retention and distribution of the PLGA formulations in rat 
breast after intraductal injection. Similar to the results from polystyrene particles, the free 
dye was cleared rapidly from the breast, while the PLGA nanoparticles were found to be 
retained in the breast up to 48 hours (Figure 13). On the other hand, PLGA microparticles 
and in-situ gel were retained in the breast for up to 4 days. This was also confirmed from 
ex-vivo imaging study of the mammary gland fluorescence from the tissue sections of 
excised breast tissue (Figure 14). Unlike the results from the polystyrene study, there was 
no detectable fluorescence in the organs for any of the treatment groups at the end of 96 
hours (Figure 15). This is not surprising considering the half-life of plasma half-life of Cy 
5.5 (2.2 hours).149 
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Figure 13: Representative fluorescence images (n=3) depicting intraductal retention of PLGA in-situ gel, microparticles, 
nanoparticles and free dye (Cy5.5) at different time points from 0-96 hours. The images were captured using in-vivo imager. 
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Figure 14:  Representative fluorescence images of PLGA formulations and free dye at the end of study. Ex-vivo images of the 
mammary glands were recorded using in-vivo imager. Mammary glands were cryosectioned (8-10 µm) and viewed under 20X 
using confocal microscope. The terminal time points were 4 hours for control, 48 hours for PLGA nanoparticles and 96 hours 
for PLGA in situ gel and microparticles.   
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Figure 15: Representative fluorescence images showing in organ biodistribution of 
PLGA in situ gel (ISG), microspheres (MS), nanoparticles (NP) and free Cy5.5 after 
intraductal injection in rat. Organs (liver, kidney, lungs, spleen and heart) and mammary 
glands were excised and imaged at 60 hours for PLGA nanoparticles, 96 hours for PLGA 
in situ gel and microparticles and 4 hours for free Cy5.5.  
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The fluorescence in the breast rapidly declined with time for both the free dye and the 
nanoparticles, while the decline was slower with microspheres and in-situ gel (Figure 15). 
The retention half-life was highest for in-situ gel, which was two-fold higher than PLGA 
microparticles (Table 11). The dye diffusion is limited by the higher viscosity of the gel 
and increases retention in the duct. The PLGA nanoparticles showed a similar half-life (20-
24 hrs) compared to polystyrene particles. The half-life for the nanoparticles is comparable 
to the half-life observed with nanoemulsions (<100nm).118 Based on our results and results 
from earlier studies, some general conclusions can be drawn regarding the effect of particle 
size on ductal retention in the breast. 22, 111, 118, 124  The ductal retention half-life of particles 
in the size range of 10-500 nm is in the range of 20-24 hrs, while the retention half-life of 
microspheres in the size range of 1-9 µm is in the range of 88-95 hrs. As the particle size 
increases, the particles undergo hindered diffusion through the ducts. However, further 
studies with additional size ranges in the nanometer and micron range are required to 
confirm these findings. The higher size range will be limited by the diameter of the ductal 
opening (0.5-2 mm) to prevent particles from blocking the duct.118  
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Figure 16: Fluorescence intensity profiles of PLGA in-situ gel, microparticles, 
nanoparticles expressed as percentage of initial fluorescence. Free Cy5.5 was used as a 
control. The data represents mean ± S.D (n = 3). * indicates statistical significance from 
free Cy5.5 using students t-test at (p <0.05) 
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Table 11:  Kinetic parameters of Cy 5.5 loaded PLGA formulations.  
Formulation k (h-1) t ½ (hrs) 
PLGA In situ gel 0.004 ± 0.002 ab 192.5 ± 11.11 ab 
PLGA Microparticles 0.008 ± 0.002 ab  88.35 ± 8.76 ab  
PLGA Nanoparticles 0.02 ± 0.001 a 24.23 ± 1.12 
Cy 5.5  0.40 ± 0.03 1.70 ± 0.16 
Each value represents mean ± S.D (n = 3). ‘k’ is the elimination rate constant; t1/2 is the 
retention half-life, i.e. time at which the fluorescence intensity is 50% of the initial value. 
‘a’ is significant in comparison to Cy 5.5; ‘b’ is significant in comparison to PLGA 
nanoparticles. The values are significant at p<0.05.   
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The whole mount showed that the formulations were distributed throughout the ductal tree 
(Figure 17). To further confirm that the formulations did not block the duct, we injected 
crystal violet along with the three formulations. The formulations did not affect the crystal 
violet distribution in the ductal tree, suggesting that the formulations do not block the ducts 
in the breast (Figure 18).  
 
Histopathological assessments were performed on H&E stained breast tissue sections to 
determine the effect of the formulations on the tissue morphology. Similar to the untreated 
mammary gland, ductal architecture was maintained in all the formulations group; there 
was no damage to epithelial lining, nor any cellular detachment was observed (Figure 19). 
However, scattered inflammatory cells in the surrounding stromal tissue were observed in 
the in-situ gel group. Notably, this inflammatory influx was also observed in NMP-treated 
group indicating that this minor inflammatory reaction could be possibly attributed to the 
solvent (NMP) used for the gel formulation and warrants the need for testing other 
alternative solvent-based gel formulations including aqueous-based gels for overcoming 
the inflammatory response.
84 
 
 
 Figure 17: Mammary whole mount 30 minutes after intraductal injection of free dye and PLGA formulations. The images 
were viewed under 20X using confocal microscope. 
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Figure 18: Intraductal distribution of crystal violet after mixing with PLGA formulations 
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Figure 19:  H&E stained sections (5µm) of mammary glands after treatment with PLGA formulations. Images were viewed in 
a light microscope under 10X. MS- microspheres; NP- nanoparticles; MG is mammary gland; ISG- in-situ gel; NMP- N-
methyl pyrrolidone. 
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Typically, DCIS is localized to a single duct, and therefore it is important to ensure that the 
drug distributes to the entire ductal tree including the terminal buds, where the majority of 
pre-cancerous lesions begin.120 The diffusion of the formulation can be influenced by the 
ductal permeability.  Gu et al in a recent study showed that the ductal retention of PEG-
doxorubicin conjugate was not significantly different between normal duct and tumor in 
the duct in a DCIS rat model.150 However, the ductal permeability can vary with the stage 
of the disease.109, 124 The ductal permeability in early stages of DCIS is similar to the normal 
ducts but is significantly altered during later stages of tumor development. 109, 124 To this 
end, the localized intraductal delivery may be more suited as a chemoprevention strategy 
for treating preneoplasia and early-stage DCIS.  
 The extrapolation of these results to humans should take into consideration the differences 
between the rodent and human breast. Rodents have a single duct, unlike multiple ducts in 
the human breast. To confirm that the results can be extrapolated to humans, we conducted 
a pilot study in pig, which has a much closer mammary gland structure to humans.151 The 
distribution and retention of PLGA formulations in the pig followed a similar trend as 
observed with the rat breast (Figure 20). Taken together, the results firmly establish that 
ductal retention in the breast can be prolonged by optimizing physicochemical properties 
of the formulation. 
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Figure 20: Representative fluorescence images (ex-vivo) of porcine mammary glands. 
Mammary glands were excised and imaged using in-vivo imager. 
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 1.3.4. Effect of PLGA formulations on retention and distribution in the regional 
lymph node  
Breast cancer spreads from the primary tumor to the regional lymph node in the axilla prior 
to systemic dissemination.152 Axillary lymph node, which is the main lymphatic basin for 
the breast, serves as a reservoir for cancer cells. 152 Therefore, we tested the lymph node 
distribution of PLGA formulations after ID injection in rats. Within 1 hour of ID injection, 
the PLGA microspheres were found in the axillary lymph node and the fluorescence was 
seen up to 2 days (Figure 21). On the other hand, the fluorescence signal from nanoparticles 
was detected only up to 24 hours. There was no detectable fluorescence in the in-situ gel 
and free dye treatment groups (Figure 21).   
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Figure 21:  Representative fluorescence images (n=3) of mammary gland, axillary lymph node and organ distribution of PLGA 
microparticles (MP), nanoparticles (NP), in-situ gel (ISG) and free Cy5.5 (top to bottom) from 1-48 hours. Images were captured 
using in-vivo imager. 1 – liver, 2-spleen, 3- lymph node, 4- mammary gland, 5- kidneys. 6-heart, 7-lungs.
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The lymph node uptake is dependent on the physicochemical properties of the molecule, 
vehicle and the route of administration.153 Lymphatic capillaries play an important role in 
the uptake of particles and macromolecules through the fenestrations and pores in the 
lymphatic capillary walls. 153 Particles in the size range of 100-1000 nm are taken up by 
the lymph nodes by pinocytosis.154 However, unlike the microparticles, the nanoparticles 
may be washed out relatively faster than from the lymph node. 155 In contrast to the 
particulate systems, the in-situ gel is primarily retained in the mammary gland and only the 
released dye is transported to the lymph node. Therefore, it is not surprising that there is 
no measurable fluorescence in the lymph node with the gel formulation, similar to the free 
dye treatment group. 
 
Chemotherapy given through systemic routes does not achieve sufficient concentration in 
the lymph nodes.153 Hence, in advanced breast cancer, the regional lymph nodes are 
surgically removed and/or subjected to radiation therapy. This is associated with painful 
lymphedema.156 The results from this study demonstrate that intraductal delivery of 
particulate formulations offers the additional advantage of targeting the lymph node to 
prevent metastasis. However, the lymph node uptake can vary with the stage of 
cancer.153 Further studies are required to understand the different factors which influence 
lymph node distribution after ID injection. Nevertheless, the results serve as a proof of 
concept to guide future formulation development for optimizing drug retention in the breast 
and regional lymph nodes.  
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 1.4. CONCLUSIONS 
Results from the study demonstrate the effect of formulation on retention in the breast and 
lymph node. Microparticles showed longer retention than nanoparticles in the breast and 
lymph node. PLGA in situ gel formulation showed the highest retention in the duct among 
the formulations tested. Taken together, the results demonstrate the proof-of-concept for 
locoregional targeting of breast and lymph nodes by optimal formulation design. Findings 
from this study can be used to develop safe and effective localized therapeutic strategies 
for breast cancer.  
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CHAPTER 2 
 
INTRADUCTAL DELIVERY OF PLGA FORMULATIONS OF TAMOXIFEN 
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2.1. BACKGROUND 
DCIS accounts for nearly 25% of all the breast cancers diagnosed in the U.S. and affects 
nearly 60,000 women each year. 157 Studies suggest that about 20-30% of DCIS will 
become invasive cancer even though there are no accurate biomarkers to predict its 
potential to progress to the invasive form. 119, 120, 157 Estrogen receptors (ERα) are 
overexpressed in 70% diagnosed DCIS cases. Estrogen is a steroid hormone that plays a 
major role in the growth and function of the breast and mediates its action through estrogen 
receptors (ERα and Erβ). 61, 66   
 
Tamoxifen (TMX) is a selective estrogen receptor modulator (SERM’s), which is widely 
used for the treatment of ERα-positive DCIS and invasive cancers. 158, 159 It is also the first 
SERM that has been successfully used in the clinic to prevent and treat breast cancer. 159 
68, 159  Tamoxifen is estimated to have saved the lives of over 400,000 women with breast 
cancer. 160 TMX is a prodrug which requires cytochrome P450 (CYP 450) to convert to its 
active metabolites 4-hydroxytamoxifen (4HT) and N-desmethyl-4-hydroxytamoxifen 
(Endoxifen) (Figure 22). These metabolites of TMX are 30-100 times more potent than 
tamoxifen. 161 One of the seminal chemopreventive trials with TMX in humans was the 
National Surgical Adjunctive Breast and Bowel project study (NSABP) chemoprevention 
study in the 1970’s. In this study, 13,388 high risk pre- and post-menopausal women were 
randomized and treated with TMX or placebo for five years. The results showed a 50% 
reduction in invasive cancer and DCIS and a non-significant decrease in bone fractures in 
volunteers treated with TMX. 160    
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Figure 22: Metabolism of Tamoxifen  
Modified from Mürdter, T.E., et al. Clinical Pharmacology & Therapeutics, 89(5), pp.708-717. 
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However, oral TMX therapy (20 mg daily for 5 years) is associated with side-effects such 
as thromboembolic events and endometrial cancer limiting its use for prevention and 
therapy.158  TMX therapy is also linked to drug resistance as they are substrates of P-
glycoprotein, breast cancer resistance protein (BCRP) and multidrug resistance associated 
protein (MRP) 161-164.  TMX has low oral bioavailability and low specificity towards tumor 
cells.161 Localized administration of TMX showed reduction in systemic side effects of 
TMX. 164, 165  In the present study, we hypothesize that long-acting intraductal TMX  
formulations will not only provide a therapeutic advantage by sustaining drug levels in the 
breast, but also reduce the side-effects associated with oral TMX.  
 
As described in the previous chapter, PLGA MS and ISG were retained in the mammary 
glands for 4 days with reduced systemic exposure compared to PLGA NP and free dye. 
Also, we found that PLGA MS and NP was transported and retained in the regional lymph 
nodes for 24 and 48 hours respectively. Building on these findings, the main objective of 
the present study is to develop intraductal PLGA formulations of TMX and to test the 
biodistribution in rats.  
 
The specific aims of the study are: 
i) Development and optimization of TMX loaded PLGA formulations 
 
ii) In-vitro characterization and release of TMX from PLGA formulations 
 
iii) Determine the biodistribution of TMX loaded PLGA formulations in rat  
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2.2. Materials and Methods 
Poly (lactic-co-glycolic acid) (LA:GA = 75:25, 75-85 KDa and 10-15 KDa, LA:GA = 
50:50, 5-10 KDa) were purchased from Akina, Inc. (West Lafayette, IN). The isoflurane 
was obtained from VetOne, Boise, ID and Veet hair removing cream was obtained from 
Reckitt Benckiser (Parsippany, NJ). All other reagents were purchased from Sigma-
Aldrich (St. Louis, MO).  
 
2.2.1. Formulation of PLGA microspheres 
Microspheres were prepared by oil-in-water (O/W) emulsion method as described in the 
earlier chapter (section 1.2.2.1). To prepare particles of different sizes, homogenization133 
(10,000 rpm for 1 minute) and overhead stirring166 (1000 rpm for 10 minutes) were used. 
50 mg TMX was used in all the formulations.  
 
2.2.2. Formulation of nanoparticles 
PLGA nanoparticles were prepared by emulsion solvent evaporation and sonication 
method134 as described in section 1.2.2.2. Tamoxifen was used in different amounts ranging 
from 10-50 mg and 100-200 mg PLGA 75:25 (10-15 KDa) were used in the formulations.  
 
2.2.3 Formulation of In situ gel 
PLGA in situ gel was prepared using a previously reported method. 137 PLGA in situ gel 
(25% w/w) was prepared using PLGA 50:50 (5-10KDa) and PLGA 75:25 (10-15 KDa), 
either alone or mixed at 1:1 w/w ratio as described in section 1.2.2.3. 
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2.2.4 HPLC 
The HPLC analysis of TMX was performed on a Waters system (Milford, MA) equipped 
with an isocratic pump, degasser, and autosampler. The compound was separated using a 
waters symmetry C18 column (Waters Corporation, Milford, USA) (4.6 mm × 150 mm, 
ID 5 μm). The mobile phase for TMX was a mixture of acetonitrile, methanol and water 
(7:3:3 v/v) containing 0.1 % v/v acetic acid and 0.01% v/v triethanolamine. The mobile 
phase was pumped at a flow rate of 0.8 ml/min and was monitored at 243 nm. The 
calibration curve of tamoxifen in acetonitrile (peak area versus drug concentration) was 
linear (R2 = 0.999) in the concentration range of 25 to 360 μg/mL for TMX. The data was 
analyzed using in built software (Breeze version 3.30 SPA).  
 
2.2.5 Determination of encapsulation and loading efficiency 
For determining encapsulation and loading efficiencies, 3 mg of MS and NP was dissolved 
in 1 ml of methylene chloride (DCM). The sample was then vortex mixed and sonicated 
for 1-2 minutes and the solvent was evaporated to dryness using gentle stream of Argon. 
The sample was then reconstituted using 1 ml acetonitrile and 10 µl was injected to RP-
HPLC determine drug concentrations using conditions as described in section 2.1.4. The 
encapsulation and loading efficiencies were calculated using the equation in section 1.2.2.4 
 
2.2.6 In vitro release study 
The release study was performed as described in 1.2.2.5. Briefly 10 mg of PLGA 
microspheres and nanoparticles were dispersed in 2 ml of release medium (PBS, pH 7.4 
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containing 0.5 % w/v SLS) in an eppendorf tube. At each time point, tubes were centrifuged 
at 10,000 rpm for 10 minutes. The supernatant was collected (1.8ml) and replaced with 
fresh release medium to maintain sink conditions. For, PLGA ISG, 500 µl of formulation 
was injected into 4 ml release medium using a 27G needle. At each time point, 2 ml of the 
medium was collected and replaced with same volume of fresh release medium to maintain 
sink conditions. The supernatant was then analyzed using HPLC as described in section 
2.1.4 to determine the TMX concentrations. 
 
2.2.7 In vivo studies 
For pharmacokinetic studies, Female Sprague Dawley rats 4-6 weeks old, 150-200 g were 
used for the study. All animal studies were performed after getting approval from IACUC 
at South Dakota State University. TMX formulations were injected (1 mg x 2 teat) into the 
inguinal mammary glands (n=3) for breast retention studies and axillary mammary glands 
for lymph node localization studies. Blood samples were (0.5 -0.1µl) were collected from 
tail vein at time points (0-14 days). The plasma was separated by centrifuging the tubes 
were then centrifuged at 10,000 rpm for 10 minutes. For lymph node localization study, 
lymph nodes were excised at time points (0 -14 days). Pharmacokinetics was performed 
using PK solutions using non compartmental analysis.  
 
2.2.8 Tissue preparation 
Before collecting the organs, the tissues were perfused with saline to remove blood from 
the organs.  The tissues were weighed and mixed with 0.1mM Tris HCl (0.1 g/ml). The 
tissue was homogenized using tissue homogenizer at 10, 000 rpm for 2-3 minutes with 
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sample kept under ice. The lymph nodes were homogenized using probe sonicator at 40W 
amplitude (2 minutes) in an eppendorf tube kept under ice. Around 100µl of the tissue 
homogenate was mixed with 400 µl of acetonitrile (1:4 w/v) to precipitate proteins. The 
mixture was vortex mixed for 30 to 60 seconds and further sonicated for 1-2 minutes. The 
sample was then centrifuged at 10,000 rpm for 10 minutes. The supernatant was collected 
and evaporated to dryness under stream of Argon. The samples were then reconstituted 
using 100 µl of 7:3 v/v of ammonium formate and acetonitrile and analyzed using LC-MS.  
The same procedure was followed for determining drug concentrations in the plasma.  
 
2.2.9 LC-MS 
Tamoxifen and two major active metabolites 4-hydroxytamoxifen and endoxifen were 
quantified by Liquid Chromatography Tandem Mass Spectrometry (LCMS) using a 
previously reported method.167 Plasma and tissue samples were analyzed using an Agilent 
1260 infinity LCMS system (Agilent, Santa Clara, CA, USA). The mobile phase (Table 
11) (Mobile phase A was 3.5mM ammonium formate, pH adjusted to 3.5 using formic acid 
and mobile phase B was acetonitrile) was pumped through reversed-phase HPLC column 
(Agilent Poroshell 120 SB-C18 column (2.1 x 100 mm, I.D 2.7µm) attached to a guard 
column (Agilent SB-C18, 2.1 x 5mm, I.D 2.7µm ) at a flow rate 0.5 ml/min using gradient 
elution method (Table 12) at 30° C. The volume of injection was 15µl and the needle was 
washed using a mixture of acetonitrile methanol and water (7:3:3) before and after each 
injection. Detection of TMX and metabolites (4HT and EDX) was performed in positive 
ion mode using a single quadrupole mass analyzer. The most intensive signal in the 
spectrum was from quasi-molecular ion [M + H]+ and hence the selected monitored ion 
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(m/z) was set to 372, 374 and 388 for tamoxifen, endoxifen and 4-hydroxytamoxifen 
respectively. The standard curve range for tamoxifen was 1 ng/ml (LLOQ) to 25 ng/mL; 
the range for 4-hydroxytamoxifen was 2.5 ng/ml (LLOQ) to 25 ng/mL; and the range for 
endoxifen was 2.5 ng/ml (LLOQ) to 50 ng/ml.  
 
2.2.10 Statistical analysis 
All the experiments were conducted in triplicate using three independent batches 
of formulations unless noted otherwise. The data is represented as mean ± standard 
deviation. One-way ANOVA was performed to determine statistical significance followed 
by Bonferroni post hoc analysis at p<0.05.  
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Table 12: Gradient elution method for TMX, 4HT and EDX 
 
Time Mobile phase A 
 
(Ammonium Formate 3.5mM, 
pH 3.5 adjusted with Formic 
acid) 
Mobile phase B 
 
100%Acetonitrile 
Flow Rate 
(ml/min) 
0 70 30 0.250 
4 30 70 0.250 
4.10 20 80 0.250 
8 20 80 0.250 
8.10 0 100 0.250 
12 0 100 0.250 
12.10 30 70 0.250 
16 70 30 0.250 
16.10 70 30 0.250 
22 70 30 0.250 
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 2.3. RESULTS AND DISCUSSION 
 The use of systemic therapy is TMX is limited due to its bothersome side- effects.158, 159  
Localized delivery of TMX is an effective way to minimize systemic toxicity associated 
with TMX. 165  Intraductal delivery has showed enhanced drug levels in the breast in several 
preclinical and clinical studies 109, 110, 119, but poor retention of drugs remains a major barrier 
for translation of this approach to clinic. 22  A more recent study showed improved efficacy 
of fulvestrant in treating ER + breast cancer in two preclinical animal models. 119 However, 
the drug was dosed 3-4 times at biweekly intervals to sustain therapeutic levels in the ducts. 
Previously, intraductal TMX did not result in chemopreventive effects as no major 
metabolites was detected in the mammary glands. However, enhanced retention time of 
TMX in the mammary glands and its biotransformation into active forms is not very well 
understood. To this end, the major goal of the study is to develop PLGA formulations of 
TMX and determine the in vivo biodistribution. This will aid in the development of an 
intraductal delivery system that can enhance drug levels in the breast, minimize systemic 
exposure and reduce the frequency of intraductal injections.  
 
2.3.1. Preparation and characterization of PLGA microspheres 
Poly (lactic-co-glycolic acid) [PLGA] microspheres (MS) were formulated using emulsion 
solvent evaporation 168 by homogenization 148 and overhead stirring methods. 166  We chose 
PLGA as the delivery system because of its extensive application in drug delivery and is 
approved by USFDA. 125  To prepare MS of different particle sizes, PLGA of copolymer 
(LA: GA) ratio of 75:25 and molecular weights 10-15 KDa (low) and 75-85 KDa (high) 
and two methods, homogenization and overhead stirring were used. With lower molecular 
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weight PLGA, homogenization and overhead stirring resulted in the formation of MS with 
particle sizes 3.36 ± 1.19 µm and 54.36 ± 12.93µm respectively (Table 13). This was 
consistent with previous finding that homogenization results in increased shear and thus 
breaks down the emulsion droplets to form particles of smaller size. 169 The drug content 
in the MS increased with increase in particle size consistent with previous findings 148. But 
when a higher molecular weight PLGA was used, homogenization resulted in lower 
particle size of 9.12 ± 3.77 µm and higher drug content 170 Higher molecular weight 
polymer has increased viscosity and hence a larger shear is required to breakdown the 
droplets to produce smaller particles. PLGA MS with particle size 9.12 ± 3.77 µm showed 
a spherical morphology (Figure 24) with higher encapsulation and loading efficiencies 
(Table 13). With high molecular weight PLGA, overhead stirring resulted in particles with 
particle size was >100 µm, which was deemed not feasible for intraductal injection (data 
not shown). Despite variabilities in the duct diameter, it is found that the diameter of the 
duct ranges from 0 - 0.2 mm. Previous studies with PLGA microspheres showed that 
particle size of 1-10 μm exhibited similar duct retention times. In this study, the goal was 
to prepare PLGA MS with particle size ~10μm that can sustain TMX release for 2 weeks.  
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Table 13: Characteristics of TMX loaded PLGA microspheres 
Formulation Particle size (µm) Zeta Potential (mV) PDI EE (%) LE (%) 
PLGA 75:25 
(10-15 KDa, H) 
  
3.36 ± 1.19 
  
-31.36 ± 0.92 
  
0.44 ± 0.09 
  
55.43 ± 1.95 
  
6.23 ± 0.14 
PLGA 75:25 
(10-15 KDa, OH) 
  
54.36 ± 12.93 
  
-30.48 ± 0.52 
  
0.44 ± 0.09 
  
73.01 ± 3.14 
  
8.89 ± 0.26 
PLGA 75:25 
(75-85 KDa, H) 
  
9.12 ± 3.77 
  
-28.36 ± 0.74 
  
0.44 ± 0.09 
  
95.35 ± 2.01 
  
10.22 ± 0.12 
PLGA is poly (lactic-co-glycolic acid), LA is lactic acid, GA is Glycolic acid, H is homogenization, OH is overhead stirring. 
Data is Mean ± SD.  Particle size calculated as an average of 30-50 microspheres using Smart Tiff software. EE is encapsulation 
efficiency, LE is loading efficiency, PDI is poly dispersity index 
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In vitro release studies were performed for all the three MS formulations described in the 
earlier. It is known that smaller particle size tends to release the contents faster because of 
the increased surface area. In the present study, PLGA MS with three different particle 
sizes (Table 13) were chosen to determine the in vitro release. PLGA MS with particle size 
3.36 ± 1.19 µm released TMX in 7 days (Figure 28). PLGA MS of particle size 54.36 ± 
12.93 µm sustained the release of TMX >7 days, but the particle size was beyond the size 
range for this study. This trend in drug release is because of the larger surface area of 
smaller microspheres and shorter diffusion path lengths. 166, 171 However, when a higher 
molecular weight of PLGA (75-85 KDa) was prepared using homogenization, the particle 
size was determined to be 9.12 ± 3.77 µm. This formulation sustained TMX release for 
>20 days and was chosen for in vivo studies (Figure 23). This is due to the slower 
hydrolytic degradation of high molecular weight polymer resulting in sustained release of 
TMX.  172  
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Figure 23: In vitro release of tamoxifen from PLGA microspheres of different particle 
sizes. Data is Mean ± SD (n=3) 
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Figure 24: Representative SEM images of PLGA formulations  
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2.3.1 Preparation and characterization of PLGA nanoparticles 
PLGA nanoparticles (NP) were prepared by emulsion solvent evaporation and sonication 
method. 134 Previous studies with polystyrene particles showed that particle size of 100-
500 nm exhibited similar retention t ½ in the ducts. So, the goal of the present study was to 
formulate PLGA NP of particle size 200-300 nm that can sustain drug release for at least 
14 days.  Initial optimization studies focused on optimizing the PLGA amounts and 
sonication parameters to prepare PLGA NP of this particle size range (data not shown). By 
keeping PLGA amount (100mg) and other parameters constant, increasing TMX amount 
resulted in increase in the particle size (Table 14).  However, by increasing the polymer 
amount to 200 mg with 10 mg of TMX resulted in the formation of PLGA NP with particle 
size 274.1 ± 6.07 with encapsulation and loading efficiencies of 91.28 ± 2.17 and 6.19 ± 
0.17 %. This was consistent with previous findings where an increase in the polymer 
amount increased the viscosity of the polymer solution (increased particle size) and 
resulted in higher drug encapsulation. 173 
 
The next goal was to determine the formulation that can sustain TMX release for ~14 days 
which was the duration of our in vivo study. PLGA NP has higher surface area and higher 
drug amounts results in burst release resulting in drug loss. 174 In vitro release of PLGA NP 
was performed for 48 hours to optimize the amount of TMX that can be loaded to PLGA 
NP (Figure 25). With 50 mg TMX, 80% of TMX was released in 48 hours. By reducing 
TMX to 15mg, the TMX release was reduced to ~60%. This was consistent with previous 
findings with PLGA nanoparticles134 where higher amounts of drug resulted in a faster drug 
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release.  However, with 10mg TMX, TMX release was sustained for 2 weeks and was 
chosen for further studies (Figure 26). This formulation also exhibited a spherical 
morphology (Figure 24) with higher encapsulation and loading efficiencies of 91.28 ± 2.17 
and 6.19 ± 0.17 % respectively (Table 14). This formulation was chosen for in vivo study.    
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Table 14: Characteristics of TMX loaded PLGA nanoparticles 
Amount of 
Tamoxifen (mg) 
Particle size (nm) Zeta Potential (mV) Encapsulation 
Efficiency (%) 
Loading Percentage 
(%) 
50 252.2 ± 4.02 -22.14 ± 2.05 77.85 ± 3.78 35.60 ± 6.17 
25 234.1 ± 2.01 -20.12 ± 0.09 61.25 ± 4.75 16.78 ± 5.09 
15 228.1 ± 9.12 -22.14 ± 1.79 58.04 ± 2.14 7.66 ± 2.45 
10* 274.1 ± 6.07 -19.17 ± 3.77 91.28 ± 2.17 6.19 ± 0.17 
Data is Mean ± SD, (n=3), PLGA 75:25 (10-15 KDa) amount 100 mg; * indicates PLGA amount of 200mg; PVA was 1%  
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Figure 25: Effect of tamoxifen loading on the burst release of tamoxifen from PLGA 
nanoparticles. Data is Mean ± SD, (n=3)   
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Figure 26: In vitro release profile of tamoxifen from optimized PLGA nanoparticles Data 
is Mean ± SD, n=3.   
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2.3.2 Preparation and characterization of PLGA in situ gel  
PLGA in situ gel (ISG) was formulated using NMP as the solvent. NMP was chosen as the 
solvent because of its extensive use in the preparation of in situ forming systems and 
because of its pharmaceutical precedence. 175 The contact of PLGA ISG with aqueous 
medium results in phase inversion and eventually the precipitation of the polymer.  135  
Initial studies focused on optimizing PLGA ISG with desired viscosity for intraductal 
injections. Reducing the polymer concentration decreased the viscosity (Table 15), but 
resulted in faster drug release175 (data not shown). Viscosity of PLGA is directly related to 
its molecular weight125 and hence PLGA with molecular weights 5-10 KDa and 10-15 KDa 
were chosen for the present study.  
 
In vitro release study showed that 20wt% of PLGA 5-10 KDa sustained release for ~10 
days (Figure 27). Blending of PLGA of different molecular weights is an effective method 
to modulate drug release 137, 146 .  In the present study a blend of PLGA 5-10 KDa 10-15 
KDa were blended at 1:1 ratio as used to formulate 25 wt% PLGA ISG. This formulation 
showed viscosity of 25cP (Table 15) and sustained TMX release for > 20 days and was 
chosen for in vivo experiments (Figure 27).  
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Table 15: Viscosity of PLGA in situ gel formulations 
Formulation Viscosity (cP) 
10 wt% PLGA 50:50 (5-10 KDa) <12.5 
20wt% PLGA 50:50 (5-10 KDa) 25 
20wt% PLGA 75:25 (10-15 KDa) 37.5 
25 wt% ISG blend 
PLGA 50:50 (5-10 KDa) & PLGA 75:25 (10-15 KDa) 
 
 
25 
cP is centipoise. Each value is Mean ± S.D, n=3 
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Figure 27: In vitro release profile of tamoxifen from 25 wt% PLGA ISG; PLGA blend is 
(5-10 KDa) and (10-15 KDa) at 1:1 wt%. Each Value is Mean ± SD, n=3.   
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2.3.4 Effect of PLGA formulations on breast retention and distribution 
To study the distribution of PLGA formulations in the breast, we used Poly (lactic-co-
glycolic acid) PLGA microspheres (MS) and nanoparticles (NP) and in situ gel (ISG). The 
formulations were injected into the 2 inguinal mammary glands (1 mg X 2 teats) and the 
concentrations of TMX and metabolites in the mammary glands were determined at days 
0.5, 1, 2, 4, 6, 7, 10 and 14.  
 
PLGA MS was retained in the mammary gland for 14 days compared to PLGA NP which 
was retained for 6 days (Figure 28). This was in accordance with our previous findings 
where particle size was found to impact drug retention in the breast. PLGA NP showed 
significantly (p<0.05) higher ke (0.0105 ± .002 hrs -1) compared to PLGA MS 
(0.0012±0.0003 hrs -1) suggesting faster diffusion of PLGA NP from the breast (Table 16).  
The diffusion of PLGA MS from the mammary ducts was slower because the larger particle 
size offered hindrance to diffusion from the mammary ducts. 22  At day 6, TMX level in 
mammary glands treated with PLGA MS were 4-fold and 6-fold higher than PLGA NP 
and free TMX respectively (Figure 28).  Moreover, the t1/2 and MRT of PLGA MS was 
~100-fold higher compared to PLGA NP and free TMX (Table 15) 
 
PLGA ISG was retained in the mammary glands for 14 days and the levels were 
significantly higher than PLGA NP and free TMX (Figure 28). The t ½ for PLGA ISG was 
significantly higher than PLGA NP and free TMX (Table 16). The amount of TMX in the 
breast for PLGA MS and ISG were found to be 1.05µg/mg and 2.20 µg/mg respectively 
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after 2 weeks following single intraductal injection.  PLGA ISG showed longer retention 
times in the breast and was found to have ke of 0.0007 hrs -1 which was lower than PLGA 
MS. The MRT of PLGA ISG was found to be 2-fold higher than PLGA MS (Table 16). 
 
Tamoxifen is a prodrug that is metabolically converted to 4-hydroxy tamoxifen176 or can 
undergo metabolic conversion to 4-hydroxy N- desmethyl tamoxifen (endoxifen)177 by 
cytochrome P450 enzymes 161 (Figure 22).  Interestingly, we observed 4-hydroxytamoxifen 
in the mammary glands treated with PLGA MS and ISG (Figure 29). The 4HT levels in 
the breast was significantly higher (p<0.05) with PLGA MS and ISG compared to free 
TMX (Figure 34).  The 4HT T max for PLGA MS and ISG of were 144 and 168 hours 
respectively.  Compared to free TMX, the C12hr was ~ 6-fold lower with PLGA MS and 
ISG.  At day 14, the amount of 4HT in the breast was 1.5 and 3.3-fold higher than free 
TMX group for PLGA MS and PLGA ISG respectively (Table 17).  No 4HT was detected 
in free TMX group and PLGA NP after 48 and 168 hours respectively. In comparison to 
PLGA nanoparticles, the level of 4HT for PLGA MS and ISG was significantly higher at 
168 hours. Free TMX showed much lower levels of 4HT till 48 hours and was below 
detection at later time points. PLGA NP showed 4HT levels till 7 days and was 
undetectable afterwards. At day 6, the levels of 4HT in mammary glands treated with 
PLGA MS were 5-fold and 2-fold higher than PLGA NP and PLGA ISG. The 4HT level 
of PLGA ISG peaked at day 7 with 4-fold higher levels than PLGA MS. At day 14, the 
4HT levels in the mammary glands were 1.5-fold and 3.5-fold higher than free TMX.  
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Previously (Figure 7), we found that particle size plays a major role in ductal retention. 
Also, it is known that hydrophobic drugs are cleared slowly from the breast than 
hydrophilic drugs111. Tamoxifen is an extremely lipophilic molecule with Log P value 
around 6. The fatty envelope of the breast tissue may serve as a drug reservoir aided by 
intra-mammary lymphatic circulation can enhance the drug retention and distribution in 
the breast.95 Previously, intraductal TMX did not show chemopreventive effects in MNU 
induced rat carcinogenic model. 109 It is fair to conclude that shorter retention time of TMX 
in the mammary glands did not facilitate the metabolism of TMX by resident CYP enzymes 
in the breast.178 However, in this study PLGA MS and ISG showed retention t ½ >200-fold 
higher in the mammary glands compared to free TMX. The CYP 3A4 enzyme is found to 
be expressed in the normal breast tissue and in breast tumors and this facilitates the 
conversion of TMX in the breast to 4 hydroxy tamoxifen. 178 From our studies, we conclude 
that retention of formulation is important determinant for this conversion of TMX in the 
breast tissue and PLGA MS and ISG with longer retention times aids in the formation of 
4HT in the breast. The role of TMX as an inducer of CYP enzymes in the breast needs also 
needs to be considered. 179  The reported IC50 value of TMX in MCF-7 cells is 3.34 – 3.71 
µg/ml and clinically relevant concentration in breast cancer patients is 1.85 µg/ml. 180, 181 
Results from this study suggests that TMX concentrations were maintained above the 
therapeutic levels following single dose of intraductal injection. Moreover, 4HT levels 
were maintained above the therapeutic levels of 4HT (IC50 – 1.52 – 6.97 ng/ml)  182 in 
mammary glands treated with PLGA ISG and MS  for 14 days.  
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Figure 28: Concentration of tamoxifen in the mammary glands from 12-336 hours. ISG is in-situ gel.  Each value is Mean ± SD, 
n=3. * is significant in comparison to free tamoxifen treatment group  
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Table 16: Pharmacokinetic parameters of tamoxifen in breast 
 
 
t ½ 
(hrs) 
 
ke 
(hrs-1) 
 
AUC 
(ng. hr/ml) 
 
AUMC 
(ng. hr2/ml) 
 
MRT 
(hrs) 
Free TMX 14.87 ± 0.04 0.020 ± 0.0005 125355.4 ± 3692.96 3654696 ± 120023.3 26.5 ± 4.3 
PLGA NP 28.61± 5.74 0.0105± 0.002 
a 
235444.4± 2744.84 9360274.65± 874274.5 39.7± 3.25 
PLGA MS 204.80±17.33 ab 0.00125± 
0.0003 ab 
1493077.05± 33219.38 ab 325087882.4± 28461186 ab 217.55± 
14.21ab 
PLGA ISG 557.13± 52.93 
abc 
0.0007± 
0.0003 ab 
2916866.333±197615.3 abc 2116349830±354466261.3 abc 755±108.64 abc 
 
t ½- plasma half-life; ke - elimination rate constant; AUC – area under the curve; AUMC- area under the first moment curve; ; 
MRT- mean residence time. TMX- is tamoxifen; NP is nanoparticle; MS is microsphere; ISG is PLGA in-situ gel. a is 
significant to Free TMX, b is significant to PLGA NP, c is significant to PLGA MS by One-way Anova followed by Bonferroni 
post-hoc test
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Figure 29: Concentration of  4-hydroxytamoxifen in the mammary glands from 12-336 hours. PLGA NP is nanoparticles; 
PLGA MS is microspheres; PLGA ISG is in situ gel. Each value is Mean ± SD, n=3. * is significant in comparison to Free 
tamoxifen treatment group by One-way Anova followed by Bonferroni post hoc analysis 
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Table 17: Pharmacokinetic parameters of 4-hydroxytamoxifen in breast 
   
t ½ 
(hrs) 
 
ke 
(hrs-1) 
 
AUC 
(ng. hr/ml) 
 
AUMC 
(ng. hr2/ml) 
 
MRT 
(hrs) 
  
Free TMX 
49.06 ± 12.37  0.0064±0.001  88.33±7.07  7689.96±1836.07  86.53±15.83  
  
PLGA NP 
 
59.12 ±23.84 
 
0.005±0.002 
 
365.15±171.19 
 
61320.1±47356.5 
 
154.5±57.27 
  
PLGA MS 
 
116.62±5.64 a 
 
0.002a 
 
1118.35±214.04 ab 
 
239585.9±18355.8 ab 
 
216.6±25.03 a 
  
PLGA ISG 
 
319.34±29.35abc 
 
0.0009±0.0001 a 
 
1959.73±840.76 ab 
 
1365242.6±485313 abc 
 
528.3±67.64 abc 
 
 
t ½- plasma half-life; ke - elimination rate constant; AUC – area under the curve; AUMC- area under the first moment curve; ; 
MRT- mean residence time. TMX- is tamoxifen; NP is nanoparticle; MS is microsphere; ISG is PLGA in-situ gel. a is 
significant to Free TMX, b is significant to PLGA NP, c is significant to PLGA MS by One-way Anova followed by Bonferroni 
post-hoc test. 
124 
 
2.3.5 Lymph node localization of PLGA formulations 
Regional lymph nodes serve as the primary site for lymphatic drainage from the breast. 
Axillary mammary glands were treated with PLGA formulations to test the role of regional 
lymph nodes in the clearance of PLGA formulations from the breast. The regional lymph 
nodes were excised and analyzed for TMX and metabolites at time points 12, 48, 168 and 
336 hours. Results showed that PLGA MS and NP drained to the lymph node and was 
retained for 336 hours and 48 hours respectively (Figure 30).  At 12 hours, TMX was 
detected with the free TMX and PLGA ISG groups and the amounts were not significant, 
but no TMX was detected at later time points. At 12 hours, the amount of TMX at regional 
lymph nodes was 3-fold higher for PLGA NP and MS respectively compared to the free 
TMX. Based on the time points chosen for the present study, PLGA NP was retained for 
48 hours and showed 12-fold higher levels at lymph nodes compared to free TMX. The 
TMX levels were highest for PLGA MS at 48 hours and this was 5-fold higher than PLGA 
NP at 12 hours. The results were in accordance with our observations in the previous 
chapter where PLGA MS and NP drained to the axillary lymph node. The presence of 
metabolites in the lymphatic system can possibly due to the recirculation metabolites from 
the plasma to the lymph nodes (Figures 31 and 32). 183 However, the levels of metabolites 
observed were much lower than TMX.  Subcutaneous administration of carboplatin 
microspheres was found to sustain drug levels in the lymph nodes. 184. In another study, a 
combination therapy of long acting injectable antiretroviral drugs was found to enhance 
drug levels in the lymph nodes. The particles are preferentially taken up by more permeable 
lymphatic capillaries and can be retained in the lymphatic vessels and transported 
throughout the lymphatic system.  The microspheres (<10µm) from the breast are 
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predominantly phagocytosed and transported to the regional lymph nodes. Lymphatic 
capillaries play  crucial role in uptake of particles (100-1000nm) through pinocytosis.154 
The transport mechanism also dictates the lymph node kinetics of microspheres and 
nanoparticles. Particles >200nm are exclusively transported to the lymph node by the 
dendritic cells.155 Unlike microspheres nanoparticles are washed out much quicker from 
the lymph nodes. 155   
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Figure 30: Lymph node concentration of Tamoxifen at different time points (12-336 hrs). 
Each Value is Mean ± SD, n=3. * is significant in comparison to free tamoxifen treatment 
group by One-way Anova followed by Bonferroni post hoc analysis. * indicates 
significance compared to free TMX. 
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Figure 31: Lymph node concentration of Endoxifen at different time points (12-336 hrs). 
Each Value is Mean ± SD, n=3 
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Figure 32: Lymph node concentration of 4-Hydroxytamoxifen at different time points 
(12-336 hrs).. Each Value is Mean ± SD, n=3 
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2.3.6 Systemic distribution 
To determine the pharmacokinetics of intraductal TMX, the plasma levels of TMX, EDX 
and 4HT were measured from 0-14 days. The plasma level of TMX was lower compared 
to 4HT and EDX (Figure 33). Free TMX showed shorter t ½ of 19.51 ± 4.24 hrs for TMX 
and was significantly lower than PLGA MS and ISG (Table 18).  Also, the C max of TMX 
for free TMX was found to be 8.9 ± 1.55ng/ml which was significantly higher (p<0.05) 
than PLGA MS and PLGA ISG which was ~3-fold higher than PLGA MS and ISG (Table 
18). These results suggest higher systemic exposure of free TMX compared to PLGA MS 
and ISG. The plasma t ½ of PLGA MS and ISG ~ 5- fold higher than free TMX which is 
due to the higher retention of TMX in the breast resulting in lower amounts of TMX 
reaching the systemic circulation. This was consistent with previous observations where 
subcutaneously administered tamoxifen loaded MS showed delayed t ½ with PLGA 
microspheres compared to subcutaneous TMX suspensions. 164 Moreover, the Tmax for 
TMX was in the decreasing order PLGA ISG<PLGA MS<PLGA NP<free TMX (Table 
18). The levels of TMX was sustained for 14 days with PLGA MS and ISG with 
significantly (p<0.05) higher MRT of 147.73 ± 59.28 and 230.2 ± 0.68 hrs for PLGA MS 
and ISG respectively. 
 
The plasma levels of TMX and two major metabolites, EDX and 4HT were in the following 
rank order, TMX<4HT<EDX following intraductal administration of TMX. TMX is 
converted to metabolites predominantly by the CYP enzymes in the liver and the delayed 
t ½ of EDX (Table 20) and 4HT (Table 18) with PLGA MS and ISG suggests a slower 
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diffusion of TMX from the breast. PLGA NP showed higher plasma levels of 4HT and 
EDX compared to PLGA MS and ISG and was below detection limit after day 5 suggesting 
the lower amounts of TMX biotransformed to the metabolites. This was consistent with 
our observations in the breast levels of TMX where PLGA NP was retained only for 7 days 
with much lower levels than PLGA MS and ISG. EDX is the major metabolite of TMX185 
and in the present study TMX levels were found to be lower than metabolites which is 
consistent with previous findings. 186 It is not very well understood whether the endoxifen 
concentrations accounts for toxicity or treatment outcome in patients taking tamoxifen. 181  
In comparison to free TMX, PLGA MS and ISG showed minimal systemic distribution of 
TMX and metabolite with highest levels found in the liver. The levels of TMX, EDX and 
4HT remained undetectable in the uterus for rats treated with PLGA MS and PLGA ISG.  
 
The TMX metabolic profile in rats resembles to that of humans. 187 However, some 
differences have been reported in the metabolic profile of rats and humans. In 
biodistribution studies, rat tissues showed equal or higher level of 4HT than endoxifen, 
whereas the levels of endoxifen were found to be the most abundant in human tissues. The 
apparent volume of distribution for tamoxifen is about 50-60 liters/kg in humans 
suggesting extensive tissue binding of tamoxifen 177. In another study, the plasma levels of 
tamoxifen and its two metabolites (N- desmethyl tamoxifen and 4-hydroxytamoxifen) was 
studied in rat and mouse models in an effort to correlate the levels to human subjects 186. 
This study showed that rats showed similar trends of TMX metabolism and tissue levels 
compared to humans. Also, the plasma level of 4HT was comparatively lower than EDX 
due to the less dominant 4-hydroxylation pathway in rats. The elimination t1/2 of tamoxifen, 
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N-desmethyltamoxifen and 4-hydroxytamoxifen in rats following a single oral dose was 
found to be 10.3, 12.1 and 17.2 hrs respectively.   
 
In another study164, tamoxifen loaded PLGA microspheres of varying hydrophobicity’s 
were administered subcutaneously in rats with similar levels observed as the present study. 
The plasma levels of tamoxifen and 4-hydroxytamoxifen was determined after a single 
subcutaneous dose of 11mg/kg tamoxifen. For the most hydrophilic system (PLGA 50/50 
microspheres), the maximum concentration of tamoxifen was obtained within 8 hours 
reaching levels of 17.1 ng/ml and 4 hydroxy tamoxifen reaching maximum levels of 6.7 
ng/ml at 11 hours. For PLGA 50/50 and 75/25 microspheres, the plasma levels of 
tamoxifen and 4 hydroxy tamoxifen were 36.14 and 8.5 ng/ml respectively but took longer 
time to reach them (23.5 and 215 hours respectively). When tamoxifen in solution was 
administered subcutaneously, TMX and 4HT levels were higher (40ng/ml at 8 hours and 
24.69 ng/ml at 48 hours respectively). However, on day 4, the presence of tamoxifen and 
4HT in plasma decreased and drug was not detected.  
 
The therapeutic levels of 4HT and EDX observed in breast cancer patients taking tamoxifen 
(20 mg) are found to be in the range of  0.38 - 6.97 ng/ml and 2.98 - 28.05 ng/ml 
respectively. 182  Taken together, results show that therapeutic levels of TMX were 
maintained in the breast tissue but not in the plasma. However, EDX and 4HT maintained 
therapeutic levels in the plasma for PLGA ISG and MS.  
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Figure 33: Plasma profile of tamoxifen after intraductal injection of formulations. The plasma concentration was measured for 
3 days for free tamoxifen, 5 days for PLGA nanoparticles and 14 days for PLGA microspheres (MS) and in situ gel. ISG is in 
situ gel. ISG is in-situ gel. Each value is Mean ± SD, n=3 
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Figure 34: Plasma profile of 4-hydroxytamoxifen after intraductal injection of PLGA formulations. The plasma concentration 
was measured for 5 days for free tamoxifen, 5 days for PLGA nanoparticles and 14 days for PLGA microspheres and in situ 
gel. ISG is in situ gel. ISG is in situ gel. Each value is Mean ± SD, n=3. * Significant in comparison to free Tamoxifen 
(p<0.05) by One-way ANOVA followed by Bonferroni post hoc analysis  
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Figure 35: Plasma profile of Endoxifen after intraductal injection of PLGA formulations. The plasma concentration was 
measured for 3 days for free tamoxifen, 5 days for PLGA nanoparticles and 14 days for PLGA microspheres and in situ gel. ISG 
is in situ gel. Each Value is Mean ± SD, n=3.  
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Table 18: Pharmacokinetic parameters of tamoxifen in plasma 
  
 
Cmax 
(ng/ml) 
 
Tmax 
(hrs) 
 
ke 
(hrs-1) 
 
t ½ 
(hrs) 
 
AUC 
(ng. hr/ml) 
 
AUMC 
(ng. hr2/ml) 
 
MRT 
(hrs) 
Free TMX 8.9 ± 1.55 0.3 0.015 ± 0.002 19.51 ± 4.24 115.8 ± 43.31 4546.37 ± 
466.103 
38.6 ± 13.10 
PLGA NP 6.9 ± 2.1 8 ± 3.4 a 0.0066 ± 
0.003 a 
56.75 ± 35.33 260.9 ± 35.41 12666.2 ± 
466.10 
47.7 ± 3.15 
PLGA MS 2.9 ± 0.72 ab 72 ab 0.0033 ± 
0.0009 a 
92.89 ± 26.08 a 211.23 ± 89.43 a 34635.5 ± 
25952.3 
147.73 ± 59.28 
ab 
PLGA ISG 3.63 ± 0.15 a 80 ±27.71 
ab 
0.0028 
±0.0007 a 
110.75 ± 31.15 a 575.96 ± 88.14 
abc 
136427 ± 
76773.6 ab 
230.2 ± 0.68 ab 
 
t ½- plasma half-life; ke - elimination rate constant; Cmax – peak plasma concentration; Tmax- time to reach peak plasma 
concentration; AUC – area under the curve; AUMC- area under the first moment curve; ; MRT- mean residence time. TMX- is 
tamoxifen; NP is nanoparticle; MS is microsphere; ISG is PLGA in-situ gel. a is significant to Free TMX, b is significant to 
PLGA NP, c is significant to PLGA MS by One-way Anova followed by Bonferroni post-hoc test. 
* 
136 
 
Table 19: Pharmacokinetic parameters of 4-hydroxytamoxifen in plasma 
 
 
Cmax 
(ng/ml) 
 
Tmax 
(hrs) 
 
ke 
(hrs-1) 
 
t ½ 
(hrs) 
 
ke 
(hrs-1) 
 
AUC 
(ng. hr/ml) 
 
AUMC 
(ng. hr2/ml) 
 
MRT 
(hrs) 
Free TMX 4.2 ± 0.115 1 0.0204 ± 0.011 33.16 ± 20.20 0.0204 ± 
0.011 
92.56 
± 19.45 
4153.8 ± 
1094.60 
43.56 ± 
3.19 
Nanoparticles 3.1 ± 0.36 a 4.6 ± 3.6 0.0077 ± 
0.0003 
38.51 ± 1.83 0.0077 ± 
0.0003 
168.1 ± 1.80 a 14150.3 ± 
1373.2 
84.03 ± 
7.39 
Microspheres 2.36 ± 0.26 ab 112 ± 42.33 0.002 ± 0.0004 157.11 ± 26.29 
ab 
0.002 ± 
0.0004 
679.2 ± 
169.94 ab 
188094.86 ± 
77107.74 
252.03 ± 
49.79 ab 
ISG 2.36 ± 0.17 ab 224 ± 42.33 ab 0.0037 ± 
0.0011 
94.27 ± 23.52 0.0037 ± 
0.0011 
813.06 ± 
97.36 ab 
220136.53 ± 
52211.86 a 
264.66 ± 
32.21 ab 
 
t ½- plasma half-life; ke - elimination rate constant; Cmax – peak plasma concentration; Tmax- time to reach peak plasma 
concentration; AUC – area under the curve; AUMC- area under the first moment curve; ; MRT- mean residence time. TMX- is 
tamoxifen; NP is nanoparticle; MS is microsphere; ISG is PLGA in-situ gel. a is significant to Free TMX, b is significant to 
PLGA NP, c is significant to PLGA MS by One-way Anova followed by Bonferroni post-hoc test
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Table 20: Pharmacokinetic parameters of endoxifen in plasma 
 
 
Cmax 
(ng/ml) 
 
Tmax 
(hrs) 
 
ke 
(hrs-1) 
 
t ½ 
(hrs) 
 
AUC 
(ng. hr/ml) 
 
AUMC 
(ng. hr2/ml) 
 
MRT 
(hrs) 
Free TMX 11.1 ± 1 2 0.0142 ± 0.0127 34.19 ± 25.42 174.26 ± 19.38 8312.83 ± 
2050.43 
46.4 ± 5.95 
Nanoparticles 4.76 ± 0.26 a 1 0.0083 ± 0.0012 37.92 ± 6.43 219.5 ± 22.3 9967 ± 1628.2 44.9 ± 2.6 
Microspheres 5 ± 1.10 a 2.33 ± 0.88 0.0013 ± 0.0003 247.27 ± 
90.59 
2177.63 ± 580.41 
ab 
1155923.16 ± 
594100.43 
472.56 ± 124.02 
ab 
ISG 5.36 ± 1.10 a 2 0.0013 ± 0.0003 292.30 ± 
112.05 
3125.06 ± 1050.41 
ab 
2279641.4 ± 
1447487.3 
592.93 ± 205.86 
ab 
 
t ½- plasma half-life; ke - elimination rate constant; Cmax – peak plasma concentration; Tmax- time to reach peak plasma 
concentration; AUC – area under the curve; AUMC- area under the first moment curve; ; MRT- mean residence time. TMX- is 
tamoxifen; NP is nanoparticle; MS is microsphere; ISG is PLGA in-situ gel. a is significant to Free TMX, b is significant to 
PLGA NP, c is significant to PLGA MS by One-way Anova followed by Bonferroni post-hoc test. 
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2.3.7 Organ distribution of TMX   
To determine the biodistribution of PLGA formulations, the organs were collected at the 
end of the study and the concentrations of TMX, 4HT and EDX were determined. Free 
TMX showed significantly higher systemic exposure of TMX compared PLGA MS and 
ISG (Figure 36). PLGA MS and ISG showed significantly (p<0.05) lower systemic 
exposure of TMX in all organs compared to free TMX. The levels of TMX in the liver and 
uterus for free TMX was ~10 fold and 3-fold higher compared to PLGA MS and ISG. 
PLGA NP showed higher systemic TMX levels than PLGA MS and ISG with higher drug 
levels present in the lungs and liver.     
The organ distribution of EDX was significantly lower for PLGA MS and ISG compared 
to free TMX (Figure 37). EDX levels were ~3 fold lower with PLGA MS and ISG 
compared to free TMX. The higher levels of EDX can be due to the relatively higher 
circulating levels of EDX in the plasma. EDX was found in the highest level in all the 
organs (Figure 37). The systemic exposure of 4HT was found to be lower than EDX with 
higher levels present in the liver were higher than TMX (Figure 38).  The 4HT organ 
distribution with the free TMX group was significantly different (p<0.05) compared to 
PLGA MS and ISG. Both the metabolites remained undetectable in the uterus for PLGA 
MS and ISG while free TMX showed ~6 fold and ~3-fold higher levels of EDX and 4HT 
with free TMX.  
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Figure 36: Biodistribution of tamoxifen after intraductal administration of PLGA 
formulations. Each value is Mean ± SD, n=3. * is significant compared to free TMX 
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Figure 37: Biodistribution of endoxifen after Intraductal administration of PLGA 
formulations. Data is Mean ± SD, n=3.* is significant in comparison to free TMX. 
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Figure 38: Biodistribution of 4-hydroxytamoxifen after Intraductal administration of 
PLGA formulations. Each value is Mean ± SD, n=3. * is significant compared to free 
TMX. 
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2.4 Conclusions 
Tamoxifen (TMX) loaded PLGA microspheres (MS) were formulated with particle size 
9.12 ± 3.77 µm with loading and encapsulation efficiencies of 10.22 ± 0.12% and 95.35 ± 
2.01% respectively. This formulation sustained TMX release for ~3 weeks. PLGA 
nanoparticles were formulated with loading and encapsulation efficiencies 6.19±0.17 and 
91.28±2.17% respectively. The optimized formulations sustained TMX release for ~2 
weeks.  25 wt% PLGA in situ gel with polymer blends resulted in low viscous (25cP) 
formulations and sustained TMX release for ~3 weeks. PLGA MS and ISG were retained 
in the mammary glands for 2 weeks and showed >200-fold higher t½ compared to free 
TMX. The levels of TMX in the mammary gland were maintained above the therapeutic 
levels of TMX for 2 weeks. PLGA MS and ISG generated 4-hydroxytamoxifen in the 
mammary glands at levels above the therapeutic levels of 4HT for 2 weeks. PLGA MS and 
ISG showed lower TMX levels in the plasma (<5ng/ml) for 2 weeks. The systemic 
exposure of free TMX was significantly higher with TMX, EDX and 4HT compared to 
PLGA MS and ISG.  PLGA MS and NP was transported to the regional lymph nodes and 
was retained for 2 and 14 days respectively with levels significantly higher (p<0.05) than 
Free TMX. Taken together, PLGA MS and ISG formulations enhanced TMX and 4HT 
retention in the mammary glands for 2 weeks. These formulations resulted in lower 
systemic exposure and PLGA MS and NP can potentially target regional lymph nodes.  
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A summary of the findings from this chapter is depicted below.  
 
Figure 39: Summary of findings from this chapter 
 
 
 
 
 
 
 
144 
 
 
 
 
 
 
 
CHAPTER 3 
INTRADUCTAL FORMULATIONS OF 4-HYDROXYTAMOXIFEN  
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3.1. BACKGROUND 
For more than 25 years, TMX has been the gold standard for endocrine treatment for all 
cases of estrogen receptor (ER) positive breast cancer. TMX is also the first SERM that 
has been successfully used in the clinic to prevent and treat breast cancer. 159 TMX is a 
prodrug which is extensively metabolized by cytochrome P450 enzymes to form 
metabolites with higher potencies towards estrogen receptors. 4HT is formed by 4-
hydroxylation of tamoxifen requires CYP3A4 for its metabolic conversion. 188  It is 
reported to have 100-fold more affinity towards ER and 30-100 fold more potent than TMX 
in suppressing estrogen dependent cell proliferation. 176 EDX is another major metabolite 
of TMX which has higher potency than the parent compound. 181   
Sukumar et al 109 , investigated chemopreventive effects of intraductal TMX in estrogen 
receptor–positive, MNU-induced rat mammary tumor model. Intraductal TMX did not 
show any chemopreventive effect as the metabolic conversion relied mainly on the CYP 
enzymes in the liver. 189  However, results from the previous chapter suggest that increased 
drug retention time in the mammary gland will likely have an effect on metabolic 
conversion of prodrugs like TMX in the breast. The study reports rapid diffusion of small 
molecules out of the ducts and hence the chemopreventive effects of 4HT might be limited 
because of poor drug retention in the mammary glands. CYP450 is a key enzyme for 
metabolic activation of TMX and genetic polymorphism of CYP enzymes influences the 
plasma concentrations of metabolites and clinical outcomes of patients treated with TMX. 
188 Intraductal 4HT further offers the advantage of treating patients who are susceptible to 
genetic polymorphisms of CYP enzymes.  Taken together, the main goal of the study is to 
develop long-acting formulations of 4HT and study in vivo biodistribution.  
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Based our results from the previous chapter, PLGA MS and ISG were retained in the 
mammary glands for 14 days. However, PLGA ISG showed signs of local inflammation, 
likely from the organic solvent (NMP).  Therefore, our goal was to develop an aqueous gel 
to address this issue. Thermoresponsive in situ hydrogels are attractive options for long 
term release of drugs. 190, 191 These are liquid at room temperature and forms a gel at the 
body temperature192.   
 
PLGA-PEG-PLGA is an ABA-type triblock copolymer and is the most widely studied 
thermosensitive gel because of its biodegradable and nontoxic properties. 193 However, for 
prolonged release, PLGA block is replaced with poly lactic acid (PLA), poly (e-
caprolactone) (PCL) and poly (e-caprolactone-co-lactide) (PCLA) blocks. The degradation 
times for PCLA-PEG-PCLA is much slower than PLGA-PEG-PLGA. Also, the use of CL 
(e-caprolactone) instead of LA could reduce the effect of acidic degradation products that 
can arise from using PLA alone. 193-195  In our previous study with TMX, MS and ISG alone 
sustained drug release for ~2 weeks.  In the present study, the goal was to further prolong 
the retention of 4HT in the mammary gland. The combination of micro or nanocarriers in 
thermosensitive hydrogels have been reported to further sustain drug release.196-198  Hence, 
we chose a combinatorial approach of dispersing PLGA MS in PCLA-PEG-PCLA 
thermogel to extend the drug release and retention. 
The specific aims of the study are:  
i) To develop 4HT loaded PLGA microspheres in PCLA-PEG-PCLA thermogel 
ii) Determine the pharmacokinetics of 4HT MS in gel (MSG) in rats 
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3.2. Materials and Methods 
PCLA-PEG-PCLA (1700-1500-1700) were purchased from Akina, Inc. (West Lafayette, 
IN). All the other chemicals were similar to chapters 1 and 2. 
3.2.1. Formulation of PLGA microspheres 
Microspheres were formulated as described previously in sections 1.2.2.1 and 2.2.1 using 
50 mg 4-hydroxytamoxifen.  
3.2.2. Determination of encapsulation and loading efficiency 
The encapsulation and loading efficiencies were determined as described previously in 
section 2.2.5.  
3.2.3. Formulation of PLGA microspheres in PCLA-PEG-PCLA thermogel 
To make the thermogel, the PCLA-PEG-PCLA (1700-1500-1700) was weighed and added 
to ultrapure DI water to attain a final concentration of 25 % w/v. 191   The solution was 
stirred for 24 hours at 2-8 ºC. PLGA microspheres were dispersed into PCLA-PEG-PCLA 
by gentle vortex mixing for 5-10 seconds. Different weight ratios of thermogel and MS 
were tested for optimal gelling at 37°C. Optimized PLGA microspheres (mg): PCLA: PEG: 
PCLA (mg) ratio: 1:10 w/w. Vial tilt method199 was used to confirm the gelling of the 
polymer at 37ºC. The formulations were transferred to a glass vial and were incubated at 
37°C for 10 minutes. Gelling was confirmed if there was no flow of the formulation after 
inverting the tube for 60 seconds.  
3.2.4. In vitro release study 
 PLGA microspheres containing 300 μg 4HT were dispersed in 25% w/v PCLA-PEG-
PCLA thermogel at 1:10 % w/w    ratio into a 2 ml Eppendorf tube. The formulation was 
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gently vortexed for 5-10 seconds to disperse the microspheres in thermogel. The 
formulation was incubated at 37°C for 10 minutes and allowed to gel. Afterwards, 2 ml of 
pre-warmed release medium (PBS, pH 7.4 containing 0.05 % w/v SDS) was gently added 
on top of the gel. The tube was placed in an incubator shaker (50 rpm) and 1.8ml of release 
medium was drawn at each time points and replaced with fresh release medium to maintain 
sink conditions. The supernatant was then analyzed using HPLC as described in section 
2.2.6.  
 
For thermogel alone, 4HT was dissolved in methanol and 300μg of 4HT was added to the 
thermogel and the release study was performed as described earlier. For PLGA 
microspheres, microspheres containing 300 μg of 4HT was dispersed in 2 ml release 
medium (PBS, pH 7.4 containing 0.05 % w/v SDS). At each time point, the tubes were 
centrifuged at 10,000 rpm for 10 minutes. The supernatant (1.8 ml) was collected and 
replaced with fresh release medium to maintain sink conditions.  The drug concentration 
was determined using HPLC at γ max 243nm as described in section 2.2.4.   
 
3.2.5. In vivo studies 
In vivo studies were performed as described previously in section 2.2.7. For 
pharmacokinetic studies, Female Sprague Dawley rats 4-6 weeks old, 150-200 g were used 
for the study. 4HT formulations were injected (300µg x 2 teat) into inguinal mammary 
glands for breast retention studies and into the axillary mammary glands (n=3) for lymph 
node localization studies. All the animal studies were performed after getting approval 
from the IACUC at South Dakota State University.  
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3.2.6. Sampling and tissue preparation 
The sampling and tissue preparations were performed using the same methodology as 
described previously in section 2.2.8. 
 
3.2.7. LC-MS 
LCMS method using gradient elution was the same as described previously in section 2.2.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3 . RESULTS AND DISCUSSION 
3.3.1. Preparation and characterization of formulations 
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In the present study we chose PLGA of molecular weight 75-85KDa and used 
homogenization to formulate microspheres of particle size 9.63 ±1.49 µm (Table 21). This 
formulation resulted in microspheres with spherical morphology (Figure 40),  higher drug 
content (10.46 ± 0.38 %) and encapsulation efficiency (92.46 ± 2.59).This is consistent 
with previous findings in which a highly lipophilic drug like 4HT (Log P = 6) tends to 
show higher entrapment in hydrophobic PLGA matrix.97, 200 PCLA-PEG-PCLA thermogel 
was chosen as the gel matrix to disperse PLGA MS owing to its slower degradation and 
ability to sustain drug release. 
 
In the present study, we chose a biodegradable, thermoreversible triblock copolymer poly 
(ɛ-caprolactone-co-lactide)-b-poly (ethylene glycol)-b-poly (ɛ-caprolactone-co-lactide) 
(PCLA–PEG–PCLA) as month long release profile was preferred. 199 The concentration of 
PCLA-PEG-PCLA thermogel was 25% w/v. Moreover, thermogel chosen for this study 
offer the benefit of lower viscosity in their sol state with slower degradation rates. 201 This 
is critical for intraductal injections where a lower viscosity with sustained release profile 
is preferred. Several ratios were tried to optimize the amount of 4HT loaded MS that can 
be dispersed in thermogel (data not shown). Optimized ratio of 4HT loaded MS and PCLA-
PEG-PCLA was determined to be 1:10 w/w.  Vial tilting method199  was performed to 
visually characterize the sol to gel transition after incubation at 37 ºC for 10 minutes.  The 
image (Figure 41) shows the sol to gel transition of MSG after incubation of the 
formulation for 10 minutes at 37 ºC.  
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Table: 21. Formulation characteristics of 4HT loaded PLGA microspheres 
Formulation Particle size (µm) Encapsulation Efficiency (%) Loading Efficiency (%) 
PLGA Microspheres 
(LA:GA-75:25),  
Mw – 75-85KDa 
 
9.63 ± 1.49  
 
92.46 ± 2.59 
 
 
10.46 ± 0.38 
 
 
PLGA is poly (lactic-co-glycolic acid), LA is lactic acid, GA is Glycolic acid, Mw is molecular weight.  
Each value represents Mean ± S.D, n=3. 
 
 
152 
 
 
 
 
 
 
 
 
 
 
Figure 40: Scanning electron microscopy image of 4HT loaded PLGA microspheres 
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Figure 41: PLGA microspheres dispersed in PCLA-PEG-PCLA thermogel before 
(left))and after (right) incubation at 37°C. 
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3.3.2 In vitro release 
The PLGA MS and thermogel released 4HT for ~ 3 weeks. On the other hand, MSG 
sustained 4HT release >4 weeks (Figure 42).  PLGA MS showed a highest burst release 
resulting in ~ 30% of 4HT released in 48 hours.  Thermogel showed lower burst release 
(~16 %) compared to MS alone. MSG showed the lowest burst release of 4HT and resulted 
in ~ 4 fold reduction compared to PLGA MS alone and ~ 2 -fold reduction compared to 
thermogel (Figure 42). The MSG sustained 4HT release for >30 days. Similar observations 
were made previously where microspheres when combined with thermogel system resulted 
in drug release of >30 days. 191   Microspheres dispersed in thermogel provides a dual 
barrier long-acting formulation. 196-198  and sustained drug release longer than MS or 
thermogel alone. MSG formulation was chosen for in vivo studies.  
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Figure 42: In vitro release profile of 4-hydroxy tamoxifen from PLGA microspheres, 
Thermogel is PLGA microspheres dispersed in PCLA-PEG-PCLA thermogel; MS is 
microspheres; PLGA is poly (lactic-co-glycolic acid). Data is Mean ± SD, n=3 
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3.3.3. Pharmacokinetics and in vivo biodistribution 
To study the pharmacokinetics, MSG and free 4HT in corn oil was injected into two 
mammary glands (300 µg per teat x 2 teats) and the concentrations of 4HT and EDX were 
measured from 0-14 days. The duration study was consistent with previous study with 
TMX.  The axillary mammary glands were chosen to study the lymph node localization of 
4HT.  
 
MSG sustained plasma levels for both 4HT and EDX for 14 days, while no 4HT or EDX 
was detected with free 4HT after days 7 and 9 respectively (Figures 43, 44). For free 4HT, 
the plasma t ½ was 31.83 ± 8.08 hrs and this was significantly shorter (p<0.05) than MSG 
(104.12 ± 18.30 hrs). The elimination rate constant (ke) for MSG was also significantly 
(p<0.05) lower in comparison to free 4HT (Table 22) suggesting a slower diffusion of 4HT 
from mammary glands treated with MSG.  This was also evident from the plasma 
concentrations where free 4HT showed higher peak plasma levels compared to MSG. Free 
4HT exhibited a higher Cmax of 29.7 ± 2.9 ng.hr/ml and was reached earlier (T max of  2 hrs) 
compared to the Cmax observed with MSG (21.5 ± 3.01 ng.hr/ml) with a delayed T max (72 
hrs).  4HT was undetectable in the free 4HT group after day 7 (Figure 43), whereas MSG 
prolonged 4HT levels for 14 days (Figure 43) in the plasma. Similarly, other 
pharmacokinetic parameters such as AUC0-α and MRT for 4HT were significantly higher 
for MSG suggesting longer retention of drug in the plasma (Table 22).  
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EDX is a major metabolite of 4HT and requires CYP enzyme system for its metabolic 
conversion. 202  EDX levels were found to be higher in the plasma for both free 4HT and 
MSG (Table 22). The Cmax for EDX for free 4HT was higher than MSG (Table 23). Free 
4HT showed significantly lower (p<0.05) t ½ for EDX (45.43 ± 22.42 hrs) compared to 
MSG (302.58 ± 41.91 hrs).  For free 4HT, no EDX was detected after day 9 (Figure 41), 
while MSG sustained EDX concentration in the plasma for 14 days (Figure 42).  
 
The therapeutic levels of 4HT and EDX in the plasma observed in breast cancer patients 
taking tamoxifen (20 mg) are found to be in the range of 0.38 - 6.97 ng/ml and 2.98 - 
28.05 ng/ml respectively. The reported IC50 values of 4HT and EDX on MCF-7 cells are 
reported to be 1.52 - 6.97 ng/ml for 4HT and 2.98 – 70.19 ng/ml for EDX. 182 In the 
present study, MSG sustained both 4HT and EDX levels within the range of the reported 
IC50 value for both the drugs.  Taken together, MSG sustained therapeutic levels of EDX 
and 4HT in the plasma.  
 
At day 14, the concentration of 4HT retained in the mammary gland was 5-fold higher than 
free 4HT (Figure 43). No 4HT was detected with free 4HT at day 14. EDX was detected 
in the mammary glands treated with MSG at day 14 (Figure 44). Previously, intraductal 
4HT did not result the formation of EDX in the mammary glands.109 However, results from 
this study suggest that formulations that can sustain 4HT levels in the mammary glands is 
a critical factor for conversion of 4HT to EDX.  Moreover, the levels of EDX in the 
mammary glands treated with MSG was much higher than the reported IC50 value of EDX 
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in MCF-7 cells181. This was consistent with our observations in the previous chapter where 
TMX was converted to 4HT in the mammary glands by CYP enzymes178  treated with MS 
and ISG.  
 
In vivo biodistribution study after 14 days showed higher levels of EDX compared to 4HT 
for MSG (Figure 50).  No uterine exposure was detected with MSG. At day 14, no 4HT or 
EDX were detected in organs treated with free 4HT suggesting faster clearance of EDX 
and 4HT compared to MSG. Lymph node localization study showed that 4HT was 
transported to the regional lymph nodes and was retained for 14 days in rats treated with 
MSG (Figure 45). No 4HT was detected in the lymph nodes in free 4HT group. This was 
consistent with our previous findings where PLGA MS was localized in the regional lymph 
nodes for 14 days. With MSG, PLGA MS might have possibly diffused out of the gel 
matrix and transported to the regional lymph nodes. No 4HT was detected in the regional 
lymph nodes treated with free 4HT.  The levels of 4HT observed in the regional lymph 
nodes were higher than the IC50 value for 4HT on MCF- 7 cells suggesting its clinical 
significance.  Taken together, MSG sustained therapeutic levels of 4HT and EDX in the 
plasma and mammary glands. Also, PLGA MS from the MSG was transported and retained 
in the regional lymph nodes for 14 days. 
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Figure 43: Plasma drug profile of 4-hydroxytamoxifen and endoxifen following treatment with free 4-hydroxytamoxifen 
formulation. Each data point is Mean ± SD, n=3. The concentration 4-hydroxytamoxifen was undetectable after day 7 and 
endoxifen was undetectable after day 9. The two groups are not statistically significant by Students t-test (p<0.05) 
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Figure 44: Plasma drug profile of 4-hydroxytamoxifen and endoxifen following treatment with microspheres in thermogel 
formulation. Each data point is Mean ± SD, n=3.* is significant by Students t-test (p<0.05). 
0
5
10
15
20
25
30
35
40
45
0 2 4 6 8 10 12 14
C
o
n
c
e
n
tr
a
ti
o
n
 (
n
g
/m
l)
4-Hydroxytamoxifen Endoxifen
Days
*
161 
 
Table 22: Pharmacokinetic parameters of 4-hydroxytamoxifen in plasma 
Pharmacokinetic parameters of 4-hydroxytamoxifen 
  
t ½ 
(hrs) 
 
ke 
(hrs-1) 
 
Cmax 
(ng/ml) 
 
Tmax 
(hrs) 
 
AUC 
(ng. hr/ml) 
 
AUMC 
(ng. hr2/ml) 
 
MRT 
(hrs) 
Free 4HT 31.83 ± 8.08 0.009 ± 0.002 29.7 ± 2.9 2 1156.53 ± 4.36 72813.93 ± 4744.79 63.4 ± 4.85 
MS in 
Thermogel 
104.12 ± 18.39* 0.002 ±0.0004* 21.5 ± 3.01* 72* 2590.3 ± 261.57* 465544 ± 103516.95* 182.66 ± 55.98* 
t ½- plasma half-life; ke - elimination rate constant; Cmax – peak plasma concentration; Tmax- time to reach peak plasma concentration; AUC – area under 
the curve; AUMC- area under the first moment curve; ; MRT- mean residence time. MS is microspheres; Data is Mean ± SD, n=3; * is significant by 
Students t-test (p<0.05) 
 
Table 23: Pharmacokinetic parameters of endoxifen in plasma 
Pharmacokinetic parameters of Endoxifen 
  
t ½ 
(hrs) 
 
ke 
(hrs-1) 
 
Cmax 
(ng/ml) 
 
Tmax 
(hrs) 
 
AUC 
(ng. hr/ml) 
 
AUMC 
(ng. hr2/ml) 
 
MRT 
(hrs) 
Free 4HT 45.43 ± 22.42 0.007 ± 0.002 49.7 ± 13.5 24 1978.76 ± 97.32 174361.1 ± 45850.24 87.53 ± 18.63 
MS in 
Thermogel 
302.58 ± 41.91* 0.0009 ± 
0.0001* 
38.5 ± 0.73 88 ± 
13.85* 
8145.8 ± 
1465.92* 
2710550.93 ± 1064850.69* 324.3 ± 74.96* 
t ½- plasma half-life; ke - elimination rate constant; Cmax – peak plasma concentration; Tmax- time to reach peak plasma concentration; AUC – area under 
the curve; AUMC- area under the first moment curve; ; MRT- mean residence time; MS is microspheres; Data is Mean ± SD, n=3; * is significant by 
Students t-test (p<0.05)  
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Figure 45: Organ levels of 4HT  at the end of study (14 days). Data is Mean ± SD, n=3. 
 
 
Figure 46: Organ levels of EDX at the end of study (14 days). Data is Mean ± SD, n=3.. 
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3.3.4 Time dependent breast distribution study   
To determine the extent of drug retention in the breast, the mammary gland levels of 4HT 
and EDX were measured on days 7, 14 and 28.  Results showed that MSG retained 4HT 
for 28 days compared to free 4HT (Figure 47). Free 4HT was retained in the mammary 
glands for 7 days even though the levels were >10 fold lower as observed with MSG 
(Figure 47). This can be due to the highly lipophilicity of 4HT and the vehicle (corn oil) 
resulting in drug binding to the adipose tissue in the breast. 97  At day 7, the 4HT 
concentration was 12-fold higher with MSG compared to free 4HT. At day 28, MSG 
maintained 4HT concentration of 1.06 µg/mg, which is higher than the reported IC50 value 
of 4HT for MCF-7 cells. 182  
 
EDX was generated in the mammary glands treated with MSG possibly due to the 
biotransformation of 4HT by resident CYP enzymes present in the mammary glands. 178  
The mammary gland levels of EDX were highest on day 14 with levels much higher than 
the therapeutic levels of EDX (Figure 48). The therapeutic levels were maintained in the 
mammary glands treated with MSG until day 28.  The lower levels of EDX on day 7 
suggest a time dependent conversion of 4HT to EDX.  Previous studies with 4HT shows 
no enzymatic conversion which might be due to faster diffusion of 4HT out of the 
mammary glands. Another possibility is the recirculation EDX from the circulation back 
into the mammary glands. Further studies needs to be conducted to validate our findings 
and also to test other possibilities like the role of enzyme induction associated with 
SERM’s. 179  
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Figure 47: Mammary gland concentration of 4HT treated with MSG and free 4HT on 7, 
14 and 28 days. Data is Mean ± SD, n=3. 
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Figure 48: Mammary gland concentration of EDX treated with MSG on 7, 14 and 28 
days. Data is Mean ± SD, n=3. No EDX was detected in mammary glands treated with 
free 4HT.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.00
10.00
100.00
1000.00
Day 7 Day 14 Day 28
Endoxifen
C
o
n
ce
n
tr
at
io
n
  (
n
g/
m
g)
166 
 
 
Figure 49: Organ distribution of 4HT and EDX in rats treated with MSG and free 4HT 7, 14 and 28 days.  
Both free 4HT and MSG did not show detectable levels at 28 days.  Data is Mean ± SD, n=3 
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3.3.5 Time dependent lymph node retention study 
To test the role of regional lymph nodes on the transport of formulations from the breast, 
we determined the levels of 4HT at the regional lymph nodes at days 7, 14 and 28. As 
reported in the previous chapter, microsphere drained through the regional lymph nodes 
and was retained for 14 days (Figure 50).  The lymph node levels of 4HT in MSG were 30 
and 5-fold higher compared to free 4HT at days 7 and 14 respectively. EDX was present 
at very low levels in the regional lymph nodes at day 7 in mammary glands treated with 
MSG (Figure 50). According to previous studies, particle size plays a major role in 
targeting distinct subsets of immune cells and occupies distinct areas of the lymph nodes. 
Smaller particles (<200nm) are found to be associated with macrophages and larger 
particles (>200 µm) are transported to the lymph nodes by dendritic cells.203, 204  
 
Studies205, 206 have reported the improved retention of microparticles >1µm in the lymph 
node upon oral and subcutaneous administration of microspheres. In a more recent study, 
microparticles of different particle sizes were injected subcutaneously into the breast of 
healthy rabbits to characterize lymphatic transport and also to assess the location of the 
particles in the lymph node relative to the malignant cells155.  Results showed that 1µm 
particles were 20 times more retained compared to 100nm nanospheres showing the 
advantage of micrometric particles for lymph node targeted chemotherapy. This is possibly 
due to a “washout phenomenon” of the nanoparticles by the efferent lymphatic system 
where in the particles travel freely to the nodes and then exit from the nodes within the first 
few hours after injection.  
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Figure 50: Lymph node concentration of 4HT and EDX in rats treated with MSG on 7, 
14 and 28 days. 4HT was undetectable at 28 days. EDX was undetectable after 7 days. 
Data is Mean ± SD, n=3.  
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3.4. CONCLUSIONS 
4HT loaded PLGA MS with particle size 9.63 ± 1.49 µm and encapsulation and loading 
efficiencies 92.46 ± 2.59 % and 10.46 ± 0.38 % respectively were prepared. Optimal drug 
polymer ratio for PLGA microspheres and thermogel was found to be 1:10 % w/w. In vitro 
release study showed sustained release of 4HT from MSG for 1 month. Pharmacokinetic 
studies showed that MSG sustained therapeutic levels of 4HT and EDX in the mammary 
glands and plasma for 28 and 14 days respectively. MSG formulation resulted in transport 
of 4HT to the regional lymph nodes and was retained for 2 weeks. In vivo biodistribution 
study showed minimal systemic distribution of 4HT and EDX with MSG compared to free 
4HT. Taken together, this study demonstrates the feasibility of long-acting intraductal 
formulations of 4HT that can sustain therapeutic levels in the mammary glands for ~1 
month.  
A summary of the findings from this chapter is depicted below.  
 
Figure 51: Summary of findings from this chapter 
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4. SUMMARY 
The main goal of this dissertation was to demonstrate the feasibility of long-acting 
intraductal delivery system for the breast. In the first study, PS particles of 1 µm were 
retained for 3 days compared to the free dye which retained only few hours. PS particles 
of 100nm and 500nm were retained only for 2 days. PLGA formulations with particle 
size ~10µm (microspheres) and in situ forming gel systems showed retention of 4 days. 
Free dye and nanoparticles (200-500 nm) diffused out of the ducts in 2- 4 hours and 24 - 
36 hours respectively. The microspheres and in situ gel formulations showed reduced 
systemic biodistribution. The whole mount images confirmed retention of the formulation 
and distribution of formulation in the ducts. The microspheres and nanoparticles also 
retained in the regional lymph nodes for 24 and 48 hours respectively.  Based on these 
findings, tamoxifen loaded PLGA microspheres and in situ gel formulations were 
developed.  PLGA microspheres and in situ gel retained tamoxifen in the mammary 
glands for 14 days compared to free tamoxifen and PLGA nanoparticles, which was 
retained for 3 and 6 days respectively. Also, 4-hydroxytamoxifen, a major metabolite of 
tamoxifen was formed in the in the mammary glands treated with microspheres and in 
situ gel. The systemic biodistribution study showed reduced systemic exposure with 
microspheres and in situ gel. The TMX loaded PLGA nanoparticles and microspheres 
were retained in the regional lymph nodes for 2 and 14 days respectively.  
Based on these findings, the next objective focused on developing intraductal 
formulations of 4HT, a potent metabolite of TMX. Further, the goal  was to prolong drug 
retention for 1 month. PLGA microspheres were combined with thermogel to achieve this 
objective. The microsphere in gel formulation sustained 4-hydroxytamoxifen release 1 
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month. Time dependent breast distribution study showed that therapeutic levels of 4-
hydroxytamoxifen was maintained for ~1 month using this formulation.  On the other 
hand, free 4-hydroxytamoxifen was retained in the breast only for 7 days. Endoxifen, a 
major metabolite of 4-hydroxytamoxifen, was formed in the breast and the therapeutic 
levels were maintained for 28 days in the breast. Pharmacokinetic studies showed that 4-
hydroxytamoxifen and endoxifen maintained therapeutic levels in the plasma for 14 days, 
while free 4-hydroxytamoxifen showed no detectable levels of 4-hydroxytamoxifen and 
endoxifen after 7 and 9 days respectively. Taken together, the findings from this 
dissertation demonstrated the feasibility of developing long acting intraductal delivery 
systems for prevention and treatment of breast cancer.  
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5. FUTURE PROSPECTS 
The findings from this dissertation can be used to guide future formulation design and 
development of long-acting intraductal delivery systems. The future studies should focus 
on: 
• Developing other formulation approaches such as drug-polymer conjugates and 
combinatorial approaches with microspheres and/or in-situ gels to further sustain 
drug release and prolong the drug levels in the breast for > 1 month 
• Mechanistic studies to understand the transport kinetics and pathways from the 
breast to lymph nodes 
• Efficacy studies using suitable animal models including metastatic breast cancer 
models.  
• Study the pharmacokinetics of long-acting formulations in a clinically translatable 
animal model such as pig 
• Conduct long-term preclinical safety studies in animals 
• Develop and test intraductal formulations for macromolecules (biologics) and test 
the retention in mammary glands  
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